Cancer Research and Treatment

Original Articles

Breast cancer

Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study: Chunfang Hao, Xu Wang, Yehui Shi, Zhongsheng Tong, Shufen Li, Xiaodong Liu, Lan Zhang, Jie Zhang, Wenjing Meng, Li Zhang; Cancer Res Treat. 2025;57(2):434-442. Published online August 9, 2024; DOI: https://doi.org/10.4143/crt.2024.340

Purpose
Approximately 50%-74% of patients with metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer do not respond to trastuzumab, with 75% of treated patients experiencing disease progression within a year. The combination of pyrotinib and capecitabine has showed efficacy in these patients. This study evaluates the efficacy and safety of pyrotinib combined with metronomic vinorelbine for trastuzumab-pretreated HER2-positive advanced breast cancer patients.
Materials and Methods
In this phase 2 trial, patients aged 18-75 years with HER2-positive advanced breast cancer who had previously failed trastuzumab treatment were enrolled to receive pyrotinib 400 mg daily in combination with vinorelbine 40mg thrice weekly. The primary endpoint was progression-free survival (PFS), while secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
Results
From October 21, 2019, to January 21, 2022, 36 patients were enrolled and received at least one dose of study treatment. At the cutoff date, 20 experienced disease progression or death. With a median follow-up duration of 35 months, the median PFS was 13.5 months (95% confidence interval [CI], 8.3 to 18.5). With all patients evaluated, an ORR of 38.9% (95% CI, 23.1 to 56.5) and a DCR of 83.3% (95% CI, 67.2 to 93.6) were achieved. The median OS was not reached. Grade 3 adverse events (AEs) were observed in 17 patients, with diarrhea being the most common (27.8%), followed by vomiting (8.3%) and stomachache (5.6%). There were no grade 4/5 AEs.
Conclusion
Pyrotinib combined with metronomic vinorelbine showed promising efficacy and an acceptable safety profile in HER2-positive advanced breast cancer patients after trastuzumab failure.

Citations

Citations to this article as recorded by

Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal
Luca Roncati
Cancers.2025; 17(8): 1323. CrossRef

1,688 View
136 Download
1 Web of Science
1 Crossref

Gastrointestinal cancer

Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma: Yoo Na Lee, Min Kyu Sung, Dae Wook Hwang, Yejong Park, Bong Jun Kwak, Woohyung Lee, Ki Byung Song, Jae Hoon Lee, Changhoon Yoo, Kyu-Pyo Kim, Heung-Moon Chang, Baek-Yeol Ryoo, Song Cheol Kim; Cancer Res Treat. 2024;56(4):1240-1251. Published online June 19, 2024; DOI: https://doi.org/10.4143/crt.2023.977

Abstract PDF PubReader ePub: Purpose
Clinical outcomes of surgery after neoadjuvant chemotherapy have not been investigated for locally advanced pancreatic cancer (LAPC), despite well-established outcomes in borderline resectable pancreatic cancer (BRPC). This study aimed to investigate the clinical outcomes of patients with LAPC who underwent curative resection following neoadjuvant chemotherapy.
Materials and Methods
We retrospectively reviewed the records of patients diagnosed with pancreatic adenocarcinoma between January 2017 and December 2020.
Results
Among 1,358 patients, 260 underwent surgery following neoadjuvant chemotherapy. Among 356 LAPC patients, 98 (27.5%) and 147 (35.1%) of 418 BRPC patients underwent surgery after neoadjuvant chemotherapy. Compared to resectable pancreatic cancer (resectable PC) with upfront surgery, both LAPC and BRPC exhibited higher rates of venous resection (28.6% vs. 49.0% vs. 4.0%), arterial resection (30.6% vs. 6.8% vs. 0.5%) and greater estimated blood loss (260.5 vs. 213.1 vs. 70.4 mL). However, hospital stay, readmission rates, and postoperative pancreatic fistula rates (grade B or C) did not differ significantly between LAPC, BRPC, and resectable PC. Overall and relapse-free survival did not differ significantly between LAPC and BRPC patients. The median overall survival was 37.3 months for LAPC and 37.0 months for BRPC. The median relapse-free survival was 22.7 months for LAPC and 26.0 months for BRPC.
Conclusion
Overall survival time and postoperative complications in LAPC patients who underwent curative resection following neoadjuvant chemotherapy showed similar results to those of BRPC patients. Further research is needed to identify specific sub-populations of LAPC patients who benefit most from conversion surgery and to minimize postoperative complications.

2,539 View
111 Download

Special Article

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group: Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, Jee Hyun Kim; Cancer Res Treat. 2022;54(1):1-9. Published online December 13, 2021; DOI: https://doi.org/10.4143/crt.2021.1115; Correction in: Cancer Res Treat 2023;55(3):1061

Abstract PDF PubReader ePub

Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

Citations

Citations to this article as recorded by

Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital
Jin Won Kim, Hee Young Na, Sejoon Lee, Ji-Won Kim, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jaihwan Kim, Jin-Hyeok Hwang, Kihwan Hwang, Chae-Yong Kim, Yong Beom Kim, Soomin Ahn, Kyu Sang Lee, Hyojin Kim, Hye Seung Lee, So Yeo
Scientific Reports.2025;[Epub] CrossRef
Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology
Ming-Huang Chen, Wan-Shan Li, Bin-Chi Liao, Chiao-En Wu, Chien-Feng Li, Chia-Hsun Hsieh, Feng-Che Kuan, Huey-En Tzeng, Jen-Fan Hang, Nai-Jung Chiang, Tse-Ching Chen, Tom Wei-Wu Chen, John Wen-Cheng Chang, Yao-Yu Hsieh, Yen-Lin Chen, Yi-Chen Yeh, Yi-Hsin L
Journal of Cancer Research and Practice.2024;[Epub] CrossRef
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II
Sun Young Kim, Jee Hyun Kim, Tae-Yong Kim, Sook Ryun Park, Shinkyo Yoon, Soohyeon Lee, Se-Hoon Lee, Tae Min Kim, Sae-Won Han, Hye Ryun Kim, Hongseok Yun, Sejoon Lee, Jihun Kim, Yoon-La Choi, Kui Son Choi, Heejung Chae, Hyewon Ryu, Gyeong-Won Lee, Dae Youn
BMC Cancer.2024;[Epub] CrossRef
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort
I. Vanni, L. Pastorino, V. Andreotti, D. Comandini, G. Fornarini, M. Grassi, A. Puccini, E. T. Tanda, A. Pastorino, V. Martelli, L. Mastracci, F. Grillo, F. Cabiddu, A. Guadagno, S. Coco, E. Allavena, F. Barbero, W. Bruno, B. Dalmasso, S. E. Bellomo, C. M
Journal of Translational Medicine.2024;[Epub] CrossRef
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Journal of Pathology and Translational Medicine.2024; 58(4): 147. CrossRef
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Cancer Research and Treatment.2024; 56(3): 721. CrossRef
Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05
T.-Y. Kim, S.Y. Kim, J.H. Kim, H.A. Jung, Y.J. Choi, I.G. Hwang, Y. Cha, G.-W. Lee, Y.-G. Lee, T.M. Kim, S.-H. Lee, S. Lee, H. Yun, Y.L. Choi, S. Yoon, S.W. Han, T.-Y. Kim, T.W. Kim, D.Y. Zang, J.H. Kang
ESMO Open.2024; 9(10): 103709. CrossRef
Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers
Yongjun Cha, Sheehyun Kim, Sae-Won Han
Cancer Research and Treatment.2023; 55(2): 367. CrossRef
Mutational evolution after chemotherapy‐progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis
Sheehyun Kim, Yongjun Cha, Yoojoo Lim, Hanseong Roh, Jun‐Kyu Kang, Kyung‐Hun Lee, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Hwang‐Phill Kim, Seung‐Yong Jeong, Kyu Joo Park, Sae‐Won Han, Tae‐You Kim
International Journal of Cancer.2023; 153(3): 571. CrossRef
Establishing molecular pathology curriculum for pathology trainees and continued medical education: a collaborative work from the Molecular Pathology Study Group of the Korean Society of Pathologists
Jiwon Koh, Ha Young Park, Jeong Mo Bae, Jun Kang, Uiju Cho, Seung Eun Lee, Haeyoun Kang, Min Eui Hong, Jae Kyung Won, Youn-La Choi, Wan-Seop Kim, Ahwon Lee
Journal of Pathology and Translational Medicine.2023; 57(5): 265. CrossRef
Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies
Gianpiero Fasola, Maria C. Barducci, Valeria D. Tozzi, Luigi Cavanna, Saverio Cinieri, Francesco Perrone, Carmine Pinto, Antonio Russo, Anna Sapino, Francesco Grossi, Giuseppe Aprile
JCO Precision Oncology.2023;[Epub] CrossRef
Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients
Yuji SHIMODA, Takeshi NAGASHIMA, Kenichi URAKAMI, Fukumi KAMADA, Sou NAKATANI, Maki MIZUGUCHI, Masakuni SERIZAWA, Keiichi HATAKEYAMA, Keiichi OHSHIMA, Tohru MOCHIZUKI, Sumiko OHNAMI, Shumpei OHNAMI, Takeshi KAWAKAMI, Kentaro YAMAZAKI, Haruyasu MURAKAMI, H
Biomedical Research.2022; 43(4): 115. CrossRef
Clinical Implication of Molecular Tumor Board
Soohyeon Lee
The Korean Journal of Medicine.2022; 97(5): 319. CrossRef
Somatic Mutations of TP53 Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study
Jung Ho Park, Mi Jung Kwon, Jinwon Seo, Ho Young Kim, Soo Kee Min, Lee Su Kim
Journal of Breast Cancer.2022; 25(5): 379. CrossRef

11,000 View
547 Download
14 Web of Science
14 Crossref

Original Articles

Lung and Thoracic cancer

Clinical Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials: Qing Yin, Longguo Dai, Ruizhu Sun, Ping Ke, Liya Liu, Bo Jiang; Cancer Res Treat. 2022;54(3):803-816. Published online October 25, 2021; DOI: https://doi.org/10.4143/crt.2021.764

Abstract PDF Supplementary Material PubReader ePub

Purpose
This network meta-analysis (NMA) was conducted to compare the efficacy of immune checkpoint inhibitors in advanced non–small cell lung cancer (NSCLC) patients with liver metastases.
Materials and Methods
English literature was retrieved from the PubMed, American Society of Clinical Oncology, and European Society for Medical Oncology databases from January 2015 to January 2021. We pooled the overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) using an NMA and ranked treatments by the surface under the cumulative ranking curve. Publication bias was evaluated by Begg’s and Egger’s tests. STATA 15.0 was used for the sensitivity analysis, and the remaining statistical analyses were performed using R 4.0.2.
Results
Nine eligible phase III randomized controlled trials were included, including 1,141 patients with liver metastases. Pembrolizumab+chemotherapy ranked highest, followed by atezolizumab+bevacizumab+chemotherapy and nivolumab. However, no significant difference in OS rates was observed across these three treatments (HR, 0.98; 95% confidence interval [CI], 0.43 to 2.22 for pembrolizumab+chemotherapy vs. atezolizumab+bevacizumab+chemotherapy; HR, 0.91; 95% CI, 0.52 to 1.57 for pembrolizumab+chemotherapy vs. nivolumab). Regarding the PFS rate, atezolizumab+bevacizumab+chemotherapy and pembro-lizumab+chemotherapy ranked highest and no significant difference was observed between them (HR, 0.79; 95% CI, 0.36 to 1.70 for atezolizumab+bevacizumab+chemotherapy vs. pembrolizumab+chemotherapy).
Conclusion
Pembrolizumab+chemotherapy, atezolizumab+bevacizumab+chemotherapy, and nivolumab were superior to other treatments in NSCLC patients with liver metastases. These new findings may help clinicians better select therapeutic strategies for NSCLC patients with liver metastases.

Citations

Citations to this article as recorded by

The Mechanism of Lactic Acid Regulating Platelet-Derived Microparticles to Affect the Biological Characteristics of Human Lung Adenocarcinoma
红艳刘
Advances in Clinical Medicine.2025; 15(01): 274. CrossRef
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases
Fan-jie Qu, Yi Zhou, Shuang Wu
British Journal of Cancer.2024; 130(2): 165. CrossRef
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
Daisuke Hazama, Kenji Nakahama, Hiroaki Kodama, Akito Miyazaki, Koichi Azuma, Yosuke Kawashima, Yuki Sato, Kentaro Ito, Yoshimasa Shiraishi, Keita Miura, Takayuki Takahama, Satoshi Oizumi, Yoshinobu Namba, Satoshi Ikeda, Hiroshige Yoshioka, Asuka Tsuya, Y
JTO Clinical and Research Reports.2024; 5(1): 100613. CrossRef
Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer
Lingling Zhu, Xianzhe Yu, Xiaojun Tang, Chenggong Hu, Lei Wu, Yanyang Liu, Qinghua Zhou
Chinese Medical Journal.2024; 137(9): 1019. CrossRef
Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases
Vesna Ćeriman Krstić, Natalija Samardžić, Milija Gajić, Milan Savić, Biljana Šeha, Marina Roksandić Milenković, Dragana Jovanović
Current Issues in Molecular Biology.2024; 46(12): 13443. CrossRef
Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis
Huilin Xu, Pingpo Ming, Zhenyu Zhao, Nan Zhao, Dingjie Zhou, Xixian Tang, Dedong Cao
Integrative Cancer Therapies.2023;[Epub] CrossRef
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
Handai Xia, Wengang Zhang, Yuqing Zhang, Xiaoling Shang, Yanguo Liu, Xiuwen Wang
Frontiers in Oncology.2022;[Epub] CrossRef

8,250 View
261 Download
7 Web of Science
7 Crossref

Gynecologic cancer

Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities: Hasan Brau-Figueroa, Eder Arango-Bravo, Denisse Castro-Eguiluz, Tatiana Galicia-Carmona, Leopoldo Abraham Lugo-Alferez, Ivette Cruz-Bautista, Roberto Jiménez-Lima, Lucely Cetina-Pérez; Cancer Res Treat. 2022;54(2):554-562. Published online August 10, 2021; DOI: https://doi.org/10.4143/crt.2021.375

Abstract PDF Supplementary Material PubReader ePub

Purpose
The standard treatment for locally advanced cervical cancer (LACC) is concomitant chemoradiotherapy with cisplatin (CDDP) followed by brachytherapy. The presence of comorbidities are risk factors for nephrotoxicity and are associated with lower survival. Gemcitabine is a radiosensitizing drug that has shown efficacy and safety in this context. The effectiveness of concomitant chemoradiotherapy with gemcitabine was evaluated versus cisplatin in LACC patients with comorbidities and preserved renal function.
Materials and Methods
An observational, longitudinal and paired study was carried out that included patients treated between February 2003 and December 2015. The primary objectives were to evaluate response rates, progression-free survival, and overall survival; the secondary objectives were to evaluate toxicity and renal function.
Results
Sixty-three patients treated with gemcitabine at 300 mg/m² weekly and 126 patients treated with CDDP 40 mg/m² weekly were included. There were no significant differences in response rates and survival rates. Treatment with cisplatin presented a higher frequency of hematological toxicities, while gemcitabine presented a higher frequency of gastrointestinal toxicities. A decrease in glomerular filtration rate (GFR; baseline vs. 1-year post-treatment) was observed in the cisplatin group (p=0.002), while not in the gemcitabine group (p=0.667). In a multivariate analysis, it is observed that only CDDP correlates with the decrease in GFR (hazard ratio, 2.42; p=0.012).
Conclusion
In LACC patients with comorbidities, gemcitabine and CDDP show the same efficacy, with different toxicity profiles. Treatment with cisplatin is associated with a significant decrease in GFR during follow-up, compared to treatment with gemcitabine that does not decrease it.

Citations

Citations to this article as recorded by

Medical nanoscale materials for virus-induced cervical cancer therapeutic modalities: For targeting delivery
Adane Adugna, Mamaru Getinet, Gashaw Azanaw Amare, Mohammed Jemal
OpenNano.2025; 21: 100221. CrossRef
The Long Term Effects of a 12‐Session Community Exercise Program on Health Measures in Cancer Patients
Isaac Oppong, Roozbeh Naemi
Aging and Cancer.2025;[Epub] CrossRef
Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction
Silvia Alarcón-Barrios, Julissa Luvián-Morales, Denisse Castro-Eguiluz, Merari Delgadillo-González, Brenda Olivia Lezcano-Velázquez, Eder Alexandro Arango-Bravo, Laura Flores-Cisneros, Sebastián Aguiar Rosas, Lucely Cetina-Pérez
Current Problems in Cancer.2024; 48: 101041. CrossRef
Association between body composition phenotypes and treatment toxicity in women with cervical cancer undergoing chemoradiotherapy
Mariah Azevedo Aredes, Nathália Silva de Paula, Gabriela Villaça Chaves
Nutrition.2024; 127: 112539. CrossRef
Older adults with cancer and common comorbidities—challenges and opportunities in improving their cancer treatment outcomes
Weiwei Chen, Rachel D Altshuler, Phil Daschner, Carolina Salvador Morales, Diane C St. Germain, Jennifer Guida, Pataje G S Prasanna, Jeffrey C Buchsbaum
JNCI: Journal of the National Cancer Institute.2024; 116(11): 1730. CrossRef

7,223 View
159 Download
3 Web of Science
5 Crossref

Head and Neck cancer

Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01): Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun; Cancer Res Treat. 2022;54(1):109-117. Published online April 27, 2021; DOI: https://doi.org/10.4143/crt.2020.1329

Abstract PDF PubReader ePub

Purpose
Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of IC in guiding the selection of a definitive locoregional therapy.
Materials and Methods
Out of the 445 patients in multi-institutional LA-HNSCC cohort, 158 (36%) receiving IC were enrolled. The study outcome was to assess overall survival (OS) through IC responsiveness and its role to select subsequent treatments.
Results
Among 135 patients who completed subsequent treatment following IC, 74% responded to IC (complete response in 17% and partial response in 58%). IC-non-responders showed 4.5 times higher risk of mortality than IC-responders (hazard ratio, 4.52; 95% confidence interval, 2.32 to 8.81; p < 0.001). Among IC-responders, 84% subsequently received definitive concurrent chemoradiotherapy (CCRT) and OS was not differed by surgery or CCRT (p=0.960). Regarding IC-non-responders, 54% received CCRT and 46% underwent surgery, and OS was poor in CCRT (24-month survival rate of 38%) or surgery (24-month survival rate of 63%).
Conclusion
Response to IC is a favorable prognostic factor. For IC-responders, either surgery or CCRT achieved similar survival probabilities. For IC-non-responder, multidisciplinary approach was warranted reflecting patients’ preference, morbidity, and prognosis.

Citations

Citations to this article as recorded by

Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study
Zachary M. Huttinger, Emile Gogineni, Sujith Baliga, Dukagjin M. Blakaj, Priyanka Bhateja, Marcelo Bonomi, Stephen Y. Kang, Matthew O. Old, Nolan B. Seim, Kyle K. VanKoevering, Amit Agrawal, Enver Ozer, James W. Rocco, Catherine T. Haring
Oral Oncology.2025; 161: 107179. CrossRef
Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific
Ye Guo, Torahiko Nakashima, Byoung Chul Cho, Darren W.-T. Lim, Muh-Hwa Yang, Pei-Jen Lou, June Corry, Jin Ching Lin, Guo Pei Zhu, Kyung Hwan Kim, Bin Zhang, Zhiming Li, Ruey-Long Hong, Junice Yi Siu Ng, Ee Min Tan, Yan Ping Liu, Con Stylianou, Carmel Spit
Oral Oncology.2024; 148: 106657. CrossRef
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for locally advanced head and neck squamous cell carcinoma
Ping Han, Faya Liang, Pan Song, Taowei Wu, Yangyang Li, Ming Gao, Peiliang Lin, Jianming Fan, Xiaoming Huang
Holistic Integrative Oncology.2024;[Epub] CrossRef
Clinical prognostic factors to guide treatment strategy for HPV‑positive oropharyngeal cancer using treatment outcomes of induction chemotherapy: A real‑world experience
Hyun Bang, Hyeon-Jong Kim, Seung Lee, Hyun Shim, Jun Hwang, Woo Bae, Ik-Joo Chung, Sang-Hee Cho
Oncology Letters.2024;[Epub] CrossRef
Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma
Sung‐Woo Cho, Bhumsuk Keam, Keun‐Wook Lee, Ji‐Won Kim, Doo Hee Han, Hyun Jik Kim, Jeong‐Whun Kim, Dong‐Young Kim, Chae‐Seo Rhee, Yun Jung Bae, Ji‐Hoon Kim, Keun‐Yong Eom, Hong‐Gyun Wu, Yong Hwy Kim, Chae‐Yong Kim, Sun Ha Paek, Hyojin Kim, Tae‐Bin Won
International Forum of Allergy & Rhinology.2024; 14(12): 1882. CrossRef
Intra-Arterial Chemotherapy for Locally Advanced Oral Cavity Cancer
B. B. Vyzhigina, M. A. Kropotov, B. I. Dolgushin, D. A. Safarov, I. V. Pogrebnyakov, S. B. Alieva
Journal of oncology: diagnostic radiology and radiotherapy.2024; 7(3): 62. CrossRef
Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma
Francesca Huwyler, Roland Giger, Ruben Bill, Daniel Rauch, Simon Haefliger
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Response to induction chemotherapy in sinonasal malignancies: A single‐institutional experience
Sarah C. Nyirjesy, Rachel Fenberg, Margaret A. Heller, Ryan T. Judd, Michael M. Li, Brandon Koch, Marcelo Bonomi, Ricardo L. Carrau, Kyle K. VanKoevering
Head & Neck.2023; 45(6): 1445. CrossRef
Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives
Michaela Svajdova, Pavol Dubinsky, Tomas Kazda, Branislav Jeremic
Cancers.2022; 14(21): 5385. CrossRef

7,916 View
240 Download
7 Web of Science
9 Crossref

Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea: Hyo Song Kim, Chung Mo Nam, Suk-Yong Jang, Sun Kyu Choi, Minkyung Han, Seonmin Kim, Maria Victoria Moneta, Sae Young Lee, Jae Min Cho, Diego Novick, Sun Young Rha; Cancer Res Treat. 2019;51(4):1380-1391. Published online February 18, 2019; DOI: https://doi.org/10.4143/crt.2018.476

Abstract PDF Supplementary Material PubReader ePub

Purpose
A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers. The aim of the present study is to determine the incidence of localized and advanced STS in Korean patients, their treatment patterns, and the survival of patients by disease status.
Materials and Methods
The STS patient cohort was defined using National Health Insurance Service medical data from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates (Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different algorithms to the STS cohort containing localized and advanced STS cases.
Results
A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 person- years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 person-years for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS, 82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients (49.98%) received anthracycline-containing chemotherapy as initial treatment after diagnosis.
Conclusion
This study provides insights into localized and advanced STS epidemiology, treatment patterns and outcomes in Korea, which could be used as fundamental data in improving clinical outcomes of STS patients in the future.

Citations

Citations to this article as recorded by

Relative Tumor Density of Soft-Tissue Sarcoma in Korean Population: An Institutional Review
Bo Bin Cha, Jung Yup Kim, Won-Serk Kim, Ga-Young Lee, Young-Jun Choi
Annals of Dermatology.2025; 37(2): 96. CrossRef
Demographic, clinical, pathologic and treatment pattern of soft tissue sarcoma at Tikur Anbessa specialized hospital, Ethiopia - retrospective cross-sectional study
Habtamu Dessie Mitiku, Melesew Abeje, Yonas Dandena
F1000Research.2025; 14: 313. CrossRef
Factors predictive of second‐line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database
Takao Mochizuki, Masachika Ikegami, Toru Akiyama
Cancer Science.2024; 115(2): 575. CrossRef
Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives
Tae Hun Kim, Ki Hyuk Sung, So Hak Chung
Journal of the Korean Orthopaedic Association.2024; 59(1): 22. CrossRef
Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study
Yoon Jang, Hong Jeong, Chang-Bae Kong, Won Song, Wan Cho, Dae Jeon, Heyjin Kim, Sung Yang, Im Na, Hyo-Rak Lee, Hye Kang
Oncology Letters.2024;[Epub] CrossRef
Necroptosis-related lncRNA-based novel signature to predict the prognosis and immune landscape in soft tissue sarcomas
Qiuzhong Long, Zhengtian Li, Wenkang Yang, Ke Huang, Gang Du
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
Tao Li, Ying Dong, Yongzhong Wei, Shoufeng Wang, Yunxia Liu, Jia Chen, Wenhua Xiong, Nong Lin, Xin Huang, Meng Liu, Xiaobo Yan, Zhaoming Ye, Binghao Li
Clinical Cancer Research.2024; 30(19): 4310. CrossRef
Mortality patterns of soft-tissue sarcomas worldwide up to 2018, with predictions for 2025
Margherita Pizzato, Giulia Collatuzzo, Claudia Santucci, Matteo Malvezzi, Paolo Boffetta, Alessandro Comandone, Fabio Levi, Carlo La Vecchia, Paola Bertuccio, Eva Negri
European Journal of Cancer Prevention.2023; 32(1): 71. CrossRef
Chemotherapeutic drugs for soft tissue sarcomas: a review
Zhichao Tian, Weitao Yao
Frontiers in Pharmacology.2023;[Epub] CrossRef
Identification of m5C-related molecular subtypes and prediction models in the prognosis and tumor microenvironment infiltration of soft tissue sarcoma
Xianfeng Wang, Yicheng Mao, Hanlu Xu, Jiyang Chen, Xiao chen
Heliyon.2023; 9(9): e19680. CrossRef
Incidence, Treatment and Outcome of Patients with Retroperitoneal Soft‐Tissue Sarcoma in Switzerland 2005–2015: A Population‐Based Analysis
Johanna C. F. Willburger, Marco von Strauss, Caspar J. Peterson, Tracy R. Glass, Christoph Kettelhack
World Journal of Surgery.2022; 46(2): 461. CrossRef
A Necroptosis-Related lncRNA Signature Predicts Prognosis and Indicates the Immune Microenvironment in Soft Tissue Sarcomas
Binfeng Liu, Zhongyue Liu, Chengyao Feng, Chao Tu
Frontiers in Genetics.2022;[Epub] CrossRef
A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma
Zhehong Li, Honghong Zheng, Lirui Liu, Zhen Fen, Haiying Cao, Jilong Yang, Junqiang Wei
Frontiers in Oncology.2022;[Epub] CrossRef
Issues of diagnostic search of soft tissue sarcoma
A. N. Sergeev, D. A. Maksimov, A. M. Morozov, M. A. Belyak, E. V. Penyaz', M. O. Popova
Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH).2022;[Epub] CrossRef
Issues of diagnostic search of soft tissue sarcoma
A. N. Sergeev, D. A. Maksimov, A. M. Morozov, M. A. Belyak, E. V. Penyaz', M. O. Popova
Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH).2022; 12(6): 15. CrossRef
Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma
Rui Shen, Bo Liu, Xuesen Li, Tengbo Yu, Kuishuai Xu, Jinfeng Ma
BMC Cancer.2021;[Epub] CrossRef
Identification of Novel Prognostic Risk Signatures of Soft Tissue Sarcoma Based on Ferroptosis-Related Genes
Wenjing Huang, Yuhe Duan, Xiuwei Yang, Cong Shang, Xin Chen, Huanyu Zhang, Fujiang Li
Frontiers in Oncology.2021;[Epub] CrossRef
Pulmonary metastasectomy in bone and soft tissue sarcoma with metastasis to the lung
Charles A Gusho, Christopher W Seder, Nicolas Lopez-Hisijos, Alan T Blank, Marta Batus
Interactive CardioVascular and Thoracic Surgery.2021; 33(6): 879. CrossRef
Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs
Li Zhang, Xianzhe Tang, Jia Wan, Xianghong Zhang, Tao Zheng, Zhengjun Lin, Tang Liu
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Identification and Validation of Pyroptosis-Related lncRNA Signature and Its Correlation with Immune Landscape in Soft Tissue Sarcomas
Zhengjun Lin, Yiting Xu, Xianghong Zhang, Jia Wan, Tao Zheng, Hongxuan Chen, Shijie Chen, Tang Liu
International Journal of General Medicine.2021; Volume 14: 8263. CrossRef
Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea—A Sarcoma-Specific, Institutional Registry-Based Analysis
Hyehyun Jeong, Hyeon-Su Im, Wanlim Kim, Jong-Seok Lee, Si Yeol Song, Joon Seon Song, Kyung-Ja Cho, Hye Won Chung, Min Hee Lee, Jeong Eun Kim, Jin-Hee Ahn
Cancer Management and Research.2021; Volume 13: 8795. CrossRef
Characterization of Immune-Related Long Non-coding RNAs to Construct a Novel Signature and Predict the Prognosis and Immune Landscape of Soft Tissue Sarcoma
Zhengjun Lin, Ke Pang, Hongli Li, Xianghong Zhang, Jia Wan, Tao Zheng, Tang Liu, Weijun Peng
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study
Chung Ryul Oh, Jung Yong Hong, Jee Hung Kim, Ji Sung Lee, Hyo Song Kim, Tae Won Kim, Jin-Hee Ahn, Jeong Eun Kim
Targeted Oncology.2020; 15(4): 485. CrossRef
Comprehensive profiling of immune-related genes in soft tissue sarcoma patients
Chuan Hu, Bo Chen, Zhangheng Huang, Chuan Liu, Lin Ye, Cailin Wang, Yuexin Tong, Jiaxin Yang, Chengliang Zhao
Journal of Translational Medicine.2020;[Epub] CrossRef

11,774 View
252 Download
22 Web of Science
24 Crossref

Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer: Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee; Cancer Res Treat. 2019;51(1):223-239. Published online October 19, 2018; DOI: https://doi.org/10.4143/crt.2018.073

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).
Materials and Methods
Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.
Results
Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.
Conclusion
This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Citations

Citations to this article as recorded by

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, J. Wang, X. Zhou, A. Gnanasakthy, K. Taylor, A. Yusuf, I. Majer, A. Jamotte, Y.-K. Kang
ESMO Gastrointestinal Oncology.2024; 6: 100095. CrossRef
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-
Clinical and Translational Oncology.2023; 25(12): 3492. CrossRef
Reminiscence therapy-based care program alleviates anxiety and depression, as well as improves the quality of life in recurrent gastric cancer patients
Xing Wu, Weiwei Zhang
Frontiers in Psychology.2023;[Epub] CrossRef
Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
Eun Mi Lee, Paula Jiménez-Fonseca, Rocio Galán-Moral, Sara Coca-Membribes, Ana Fernández-Montes, Elena Sorribes, Esmeralda García-Torralba, Laura Puntí-Brun, Mireia Gil-Raga, Juana Cano-Cano, Caterina Calderon
Current Oncology.2023; 30(10): 9205. CrossRef
Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review
Cara Ghiglieri, Martin Dempster, Sam Wright, Lisa Graham-Wisener
BMC Palliative Care.2023;[Epub] CrossRef
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang
Gastric Cancer.2021; 24(1): 156. CrossRef
Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial
Kazumasa Fujitani, Kohei Shitara, Atsuo Takashima, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hisashi Hosaka, Yoshito Komatsu, Ken Shimada, Ryohei Kawabata, Hideki Ohdan, Yasuhiro Kode
Gastric Cancer.2021; 24(2): 467. CrossRef
Quality-of-Life Assessment in Patients Receiving Palliative Chemotherapy: Call for Action
Maheswari Senthil
Annals of Surgical Oncology.2021; 28(1): 7. CrossRef
Impact of gastric cancer treatment on quality of life of patients
Kerstin Schütte, Christian Schulz, Kristina Middelberg-Bisping
Best Practice & Research Clinical Gastroenterology.2021; 50-51: 101727. CrossRef
Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer—A Systematic Review
Sophia Kristina Rupp, Andreas Stengel
Frontiers in Psychiatry.2021;[Epub] CrossRef
Chronological changes in quality of life and body composition after gastrectomy for locally advanced gastric cancer
Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Ho Young Chung, Oh Kyoung Kwon
Annals of Surgical Treatment and Research.2020; 98(5): 262. CrossRef
Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
Hannah Christina Puhr, Eleonore Pablik, Anna Sophie Berghoff, Gerd Jomrich, Sebastian Friedrich Schoppmann, Matthias Preusser, Aysegül Ilhan-Mutlu
ESMO Open.2020; 5(2): e000623. CrossRef

11,931 View
238 Download
12 Web of Science
12 Crossref

Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer: Claudia Marchetti, Francesca De Felice, Anna Di Pinto, Alessia Romito, Angela Musella, Innocenza Palaia, Marco Monti, Vincenzo Tombolin, Ludovico Muzii, PierLuigi Benedetti Panici; Cancer Res Treat. 2018;50(3):768-776. Published online July 19, 2017; DOI: https://doi.org/10.4143/crt.2017.141

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to develop nomograms for predicting the probability of overall survival (OS) and progression-free survival (PFS) in locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical surgery.
Materials and Methods
Nomograms to predict the 5-year OS rates and the 2-year PFS rates were constructed. Calibration plots were constructed, and concordance indices were calculated. Evaluated variableswere body mass index, age, tumor size, tumor histology, grading, lymphovascular space invasion, positive parametria, and positive lymph nodes.
Results
In total 245 patients with locally advanced cervical cancer who underwent neoadjuvant chemotherapy and radical surgery were included for the construction of the nomogram. The 5-year OS and PFS were 72.6% and 66%, respectively. Tumor size, grading, and parametria status affected the rate of OS, whereas tumor size and positive parametria were the main independent PFS prognostic factors.
Conclusion
We constructed a nomogram based on clinicopathological features in order to predict 2-year PFS and 5-year OS in locally advanced cervical cancer primarily treated with neoadjuvant chemotherapy followed by radical surgery. This tool might be particularly helpful for assisting in the follow-up of cervical cancer patients who have not undergone concurrent chemoradiotherapy.

Citations

Citations to this article as recorded by

Plasma-based proteomic and metabolomic characterization of lung and lymph node metastases in cervical cancer patients
Yue Feng, Zijian Sun, Huan Zhang, Zhao Wang, Lichao Wang, Hui Ye, Xiaojing Zhang, Zhuomin Yin, Juan Ni, Jingkui Tian, Hanmei Lou, Xiaojuan Lv, Wei Zhu
Journal of Pharmaceutical and Biomedical Analysis.2025; 253: 116521. CrossRef
Analysis of prognosis and related influencing factors of different surgical approaches for early cervical cancer
Lingling Ou, Lulu He, Qiaowen Bu, Hengying Wu, Bin Wen, Xiping Luo, Xiaoshan Hong
Journal of Cancer Research and Clinical Oncology.2025;[Epub] CrossRef
Risk stratification of node-positive early-stage cervical cancer treated with radical hysterectomy followed by chemoradiotherapy: a retrospective single-center study
Shuang-Zheng Jia, Duan Yang, Xue-Jiao Yang, Rui Wang, Xi Yang, Man-Ni Huang, Ju-Sheng An
Radiation Oncology.2025;[Epub] CrossRef
Dose prediction for cervical cancer in radiotherapy based on the beam channel generative adversarial network
Hui Xie, Tao Tan, Hua Zhang, Qing Li
Heliyon.2024; 10(18): e37472. CrossRef
Systematic review and meta-analysis of prediction models used in cervical cancer
Ashish Kumar Jha, Sneha Mithun, Umeshkumar B. Sherkhane, Vinay Jaiswar, Biche Osong, Nilendu Purandare, Sadhana Kannan, Kumar Prabhash, Sudeep Gupta, Ben Vanneste, Venkatesh Rangarajan, Andre Dekker, Leonard Wee
Artificial Intelligence in Medicine.2023; 139: 102549. CrossRef
Development and validation of radiomic signature for predicting overall survival in advanced-stage cervical cancer
Ashish Kumar Jha, Sneha Mithun, Umeshkumar B. Sherkhane, Vinay Jaiswar, Sneha Shah, Nilendu Purandare, Kumar Prabhash, Amita Maheshwari, Sudeep Gupta, Leonard Wee, V. Rangarajan, Andre Dekker
Frontiers in Nuclear Medicine.2023;[Epub] CrossRef
Advanced cervical stump cancer after laparoscopic subtotal hysterectomy: a case report of imaging, laparoscopic staging and treatment approach
Dimitrios Andrikos, Argyrios Andrikos, Antoine Naem, Olga Ebertz, Rajesh Devassy, Rudy Leon De Wilde, Michael Khamou, Harald Krentel
BMC Women's Health.2023;[Epub] CrossRef
Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
Linlin Liu, Xianbo Deng, Shuang Guo, Shouhua Yang
Diagnostic Pathology.2023;[Epub] CrossRef
Influence of the Clinical Nursing Pathway on Nursing Outcomes and Complications of Cervical Carcinoma Patients Undergoing Chemotherapy via PICC
Hongxia Tang, Li Gao, Yahui Li, Zhiqian Zhang
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Current and future direction in treatment of HPV-related cervical disease
Niloofar Khairkhah, Azam Bolhassani, Reza Najafipour
Journal of Molecular Medicine.2022; 100(6): 829. CrossRef
Machine Learning of Dose-Volume Histogram Parameters Predicting Overall Survival in Patients with Cervical Cancer Treated with Definitive Radiotherapy
Zhiyuan Xu, Li Yang, Qin Liu, Hao Yu, Longhua Chen, Claudia Marchetti
Journal of Oncology.2022; 2022: 1. CrossRef
Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis
Lin Qi, Ning Li, Aimin Lin, Xiuli Wang, Jianglin Cong
Frontiers in Oncology.2022;[Epub] CrossRef
Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
Jing Liu, Guyu Tang, Qin Zhou, Weilu Kuang
Radiation Oncology.2022;[Epub] CrossRef
The comparative study for survival outcome of locally advanced cervical cancer treated by neoadjuvant arterial interventional chemotherapy or intravenous chemotherapy followed by surgery or concurrent chemoradiation
Yi Sun, Gailing Li, Panpan Hai, Yuan Cao, Pin Han, Yuchen Liu, Jing Wen, Yuanpei Wang, Xiaoran Cheng, Fang Ren
World Journal of Surgical Oncology.2022;[Epub] CrossRef
Pembrolizumab for advanced cervical cancer: safety and efficacy
Francesca De Felice, Elena Giudice, Giulia Bolomini, Maria Grazia Distefano, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
Expert Review of Anticancer Therapy.2021; 21(2): 221. CrossRef
Nomograms predicting the overall survival and cancer-specific survival of patients with stage IIIC1 cervical cancer
Yifan Feng, Ye Wang, Yangqin Xie, Shuwei Wu, Yuyang Li, Min Li
BMC Cancer.2021;[Epub] CrossRef
Comparison of therapeutic effects of chemo-radiotherapy with neoadjuvant chemotherapy before radical surgery in patients with bulky cervical carcinoma (stage IB3 & IIA2)
Setareh Akhavan, Abbas Alibakhshi, Mahdieh Parsapoor, Abbas Alipour, Elahe Rezayof
BMC Cancer.2021;[Epub] CrossRef
Macleayins A From Macleaya Promotes Cell Apoptosis Through Wnt/β-Catenin Signaling Pathway and Inhibits Proliferation, Migration, and Invasion in Cervical Cancer HeLa Cells
Chunmei Sai, Wei Qin, Junyu Meng, Li-Na Gao, Lufen Huang, Zhen Zhang, Huannan Wang, Haixia Chen, Chaohua Yan
Frontiers in Pharmacology.2021;[Epub] CrossRef
Nomogram Predicting Overall Survival in Patients with FIGO II to III Squamous Cell Cervical Carcinoma Under Radical Radiotherapy: A Retrospective Analysis Based on 2018 FIGO Staging
Lele Zang, Qin Chen, Xiaozhen Zhang, Xiaohong Zhong, Jian Chen, Yi Fang, An Lin, Min Wang
Cancer Management and Research.2021; Volume 13: 9391. CrossRef
Prediction of early response to concurrent chemoradiotherapy in cervical cancer: Value of multi-parameter MRI combined with clinical prognostic factors
Xiaomin Zheng, Weiqian Guo, Jiangning Dong, Liting Qian
Magnetic Resonance Imaging.2020; 72: 159. CrossRef
Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study
Guilan Xie, Ruiqi Wang, Li Shang, Cuifang Qi, Liren Yang, Liyan Huang, Wenfang Yang, Mei Chun Chung
BMC Cancer.2020;[Epub] CrossRef
SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines
Xing Chen, Dongsheng Xiong, Liya Ye, Huichun Yang, Shuangshuang Mei, Jinhong Wu, Shanshan Chen, Ruoran Mi
Cancer Chemotherapy and Pharmacology.2019; 83(4): 603. CrossRef
Systemic therapy in cervical cancer: 30 years in review
Michalis Liontos, Anastasios Kyriazoglou, Ioannis Dimitriadis, Meletios-Athanasios Dimopoulos, Aristotelis Bamias
Critical Reviews in Oncology/Hematology.2019; 137: 9. CrossRef
Adjuvant chemoradiotherapy versus radiotherapy in cervical cancer patients with intermediate-risk factors: A systematic review and meta-analysis
Meng Li, Mengyang Hu, Yuanjian Wang, Xingsheng Yang
European Journal of Obstetrics & Gynecology and Reproductive Biology.2019; 238: 1. CrossRef
Neoadjuvant chemotherapy followed by radical hysterectomy for stage IB2-to-IIB cervical cancer: a retrospective cohort study
Lei Li, Ming Wu, Shuiqing Ma, Xianjie Tan, Sen Zhong
International Journal of Clinical Oncology.2019; 24(11): 1440. CrossRef
Immune check-point in cervical cancer
F. De Felice, C. Marchetti, I. Palaia, R. Ostuni, L. Muzii, V. Tombolini, P. Benedetti Panici
Critical Reviews in Oncology/Hematology.2018; 129: 40. CrossRef

10,112 View
398 Download
32 Web of Science
26 Crossref

Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib: Jeong-Ju Yoo, Goh Eun Chung, Jeong-Hoon Lee, Joon Yeul Nam, Young Chang, Jeong Min Lee, Dong Ho Lee, Hwi Young Kim, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Seoul Liver Group; Cancer Res Treat. 2018;50(2):366-373. Published online May 15, 2017; DOI: https://doi.org/10.4143/crt.2017.126

Abstract PDF PubReader ePub

Purpose
Advanced hepatocellular carcinoma (HCC) is associated with various clinical conditions including major vessel invasion, metastasis, and poor performance status. The aim of this study was to establish a prognostic scoring system and to propose a sub-classification of the Barcelona-Clinic Liver Cancer (BCLC) stage C.
Materials and Methods
This retrospective study included consecutive patientswho received sorafenib for BCLC stage C HCC at a single tertiary hospital in Korea. A Cox proportional hazard model was used to develop a scoring system, and internal validationwas performed by a 5-fold cross-validation. The performance of the model in predicting risk was assessed by the area under the curve and the Hosmer-Lemeshow test.
Results
A total of 612 BCLC stage C HCC patients were sub- classified into strata depending on their performance status. Five independent prognostic factors (Child-Pugh score, α-fetoprotein, tumor type, extrahepatic metastasis, and portal vein invasion) were identified and used in the prognostic scoring system. This scoring system showed good discrimination (area under the receiver operating characteristic curve, 0.734 to 0.818) and calibration functions (both p < 0.05 by the Hosmer-Lemeshow test at 1 month and 12 months, respectively). The differences in survival among the different risk groups classified by the total score were significant (p < 0.001 by the log-rank test in both the Eastern Cooperative Oncology Group 0 and 1 strata).
Conclusion
The heterogeneity of patientswith BCLC stage C HCC requires sub-classification of advanced HCC. A prognostic scoring system with five independent factors is useful in predicting the survival of patients with BCLC stage C HCC.

Citations

Citations to this article as recorded by

Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib
Jun Sun, Dongdong Xia, Wei Bai, Xiaomei Li, Enxing Wang, ZhanXin Yin, Guohong Han
Frontiers in Oncology.2024;[Epub] CrossRef
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Ji W. Han, Soon K. Lee, Jung H. Kwon, Soon W. Nam, Hyun Yang, Si H. Bae, Ji H. Kim, Heechul Nam, Chang W. Kim, Hae L. Lee, Hee Y. Kim, Sung W. Lee, Ahlim Lee, U I. Chang, Do S. Song, Seok-Hwan Kim, Myeong J. Song, Pil S. Sung, Jong Y. Choi, Seung K. Yoon,
Clinical Cancer Research.2024; 30(13): 2812. CrossRef
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi
Journal of Liver Cancer.2023; 23(1): 177. CrossRef
Development and validation of web‐based prognostic nomograms for massive hepatocellular carcinoma (≥10 cm): A retrospective study based on the SEER database
Guizhong Huang, Qiaohong Lin, Pengfei Yin, Kai Mao, Jianlong Zhang
Cancer Medicine.2023; 12(12): 13167. CrossRef
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
Xiaomi Li, Xiaoyan Ding, Mei Liu, Jingyan Wang, Wei Li, Jinglong Chen
The Oncologist.2023; 28(10): e942. CrossRef
Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal
Li Li, Xiaomi Li, Wendong Li, Xiaoyan Ding, Yongchao Zhang, Jinglong Chen, Wei Li
BMC Cancer.2022;[Epub] CrossRef
Identification and validation of a prognostic model of necroptosis-related lncRNAs in hepatocellular carcinoma
Min Chen, Guang-Bo Wu, Shan Hua, Zhi-Feng Zhao, Hong-Jie Li, Meng Luo
Frontiers in Genetics.2022;[Epub] CrossRef
Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy
Jian-Xu Li, Mei-Ling He, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ying Long, Jian-Hong Zhong, Rui-Jun Zhang, Chun-Feng Liang, Ya-Dan Pang, Jun-Kun He, Qian-Qian Chen, Jin-Xia Weng, Shi-Xiong Liang, Bang-De Xiang
BMC Gastroenterology.2022;[Epub] CrossRef
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
Giovanni Marasco, Francesco Poggioli, Antonio Colecchia, Giuseppe Cabibbo, Filippo Pelizzaro, Edoardo Giannini, Sara Marinelli, Gian Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Foschi, Marc
Cancers.2021; 13(11): 2677. CrossRef
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
Young Youn Cho, Su Jong Yu, Hye Won Lee, Do Young Kim, Wonseok Kang, Yong-Han Paik, Pil Soo Sung, Si Hyun Bae, Su Cheol Park, Young Seok Doh, Kang Mo Kim, Eun Sun Jang, In Hee Kim, Won Kim, Yoon Jun Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 613. CrossRef
Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma
Chen Jin, Rui Li, Tuo Deng, Jialiang Li, Yan Yang, Haoqi Li, Kaiyu Chen, Huihua Xiong, Gang Chen, Yi Wang
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Construction and validation of an N6‑methyladenosine‑associated prognostic signature in hepatocellular carcinoma
Peng Zhu, Qianqian Ren, Nan He, Cheng Zhou, Qianna Jin, Zhao Gong
Oncology Letters.2021;[Epub] CrossRef
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tim A. Labeur, Sarah Berhane, Julien Edeline, Jean‐Frederic Blanc, Dominik Bettinger, Tim Meyer, Jeroen L. A. Van Vugt, David W. G. Ten Cate, Robert A. De Man, Ferry A. L. M. Eskens, Alessandro Cucchetti, Laura J. Bonnett, Otto M. Van Delden, Heinz‐Josef
Liver International.2020; 40(1): 215. CrossRef
A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients
Tingting Zhang, Zhe Liu, Xiangqian Zhao, Zhiyuan Mao, Li Bai
Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 2246. CrossRef
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
Yeon Joo Kim, Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Young-Suk Lim, Han Chu Lee, Jong Hoon Kim, Sang Min Yoon
Radiotherapy and Oncology.2019; 141: 95. CrossRef
Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
Bo Hyun Kim, Joong-Won Park
Journal of Korean Medical Science.2018;[Epub] CrossRef

9,763 View
308 Download
18 Web of Science
16 Crossref

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study: Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin-Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong-Churl Suh, Yeul Hong Kim; Cancer Res Treat. 2018;50(1):175-182. Published online March 30, 2017; DOI: https://doi.org/10.4143/crt.2016.535

Abstract PDF PubReader ePub

Purpose
This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence.
Materials and Methods
A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients.
Results
A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes.
Conclusion
GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.

Citations

Citations to this article as recorded by

Real‐World Outcomes of Patients Treated With Gemcitabine Using Standardized Dose and Rate and Docetaxel for Advanced Soft Tissue Sarcoma in an Australian Sarcoma Center
Isabella Wilson, Madeleine Strach, Vivek Bhadri, Michelle Harrison, Whiter Tang, Peter Grimison
Asia-Pacific Journal of Clinical Oncology.2025; 21(3): 305. CrossRef
A review of cutaneous angiosarcoma: epidemiology, diagnosis, prognosis, and treatment options
Kohei Yamakawa, Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Yukie Yamaguchi, Naoya Yamazaki
Japanese Journal of Clinical Oncology.2025;[Epub] CrossRef
Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma
Shuang Liang, Lanting Ji, Zhenyuan Yu, YaHsin Cheng, Ruifang Gao, Wenpeng Yan, Fang Zhang
Hereditas.2024;[Epub] CrossRef
Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives
Tae Hun Kim, Ki Hyuk Sung, So Hak Chung
Journal of the Korean Orthopaedic Association.2024; 59(1): 22. CrossRef
Leiomyosarcoma of stomach extending to gastroesophageal junction and distal esophagus as a rare cause of dysphagia: a case report
Lilamani Rajthala, Sagar Gyawali, Sabin Banmala, Surendra Shah
Annals of Medicine & Surgery.2024; 86(5): 3133. CrossRef
Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma
Prapassorn Thirasastr, Heather Lin, Behrang Amini, Wei‐Lien Wang, Jeffrey M. Cloutier, Elise F. Nassif, Emily Z. Keung, Christina L. Roland, Barry Feig, Dejka Araujo, Robert S. Benjamin, Anthony P. Conley, John A. Livingston, Joseph Ludwig, Shreyaskumar P
Cancer Medicine.2023; 12(4): 4282. CrossRef
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
Tuyen Duong Thanh Nguyen, Yan Wang, Tuyen N. Bui, Rossana Lazcano, Davis R. Ingram, Min Yi, Varshini Vakulabharanam, Linjie Luo, Marc A. Pina, Cansu Karakas, Mi Li, Nicole M. Kettner, Neeta Somaiah, Peter J. Hougton, Osama Mawlawi, Alexander J. Lazar, Kel
Cancer Research.2023; 83(6): 939. CrossRef
A competing risk-based nomogram to predict cancer-specific survival in patients with retroperitoneal leiomyosarcoma
Qian Fang, Guojing Cai, Guizeng Chen, Xiang Xu, Haifeng Zeng, Yulong He, Shirong Cai, Hui Wu
Heliyon.2023; 9(6): e16867. CrossRef
Chemotherapeutic drugs for soft tissue sarcomas: a review
Zhichao Tian, Weitao Yao
Frontiers in Pharmacology.2023;[Epub] CrossRef
Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcoma
Szu-Yun Niu, Lou Sun, Shih-Tien Hsu, Sheau-Feng Hwang, Chih-Ku Liu, Yu-Hsiang Shih, Ting-Fang Lu, Yen-Fu Chen, Li-Ching Lai, Pei-Lun Chang, Chien-Hsing Lu
Frontiers in Oncology.2023;[Epub] CrossRef
Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature
Siran Yang, Wenqing Wang, Nan Bi, Zongmei Zhou, Qinfu Feng, Zefen Xiao, Dongfu Chen, Jun Liang, Jima Lu, Jianyang Wang, Xin Wang, Jingbo Wang, Yong Yang, Ningning Lu, Hongxing Zhang, Luhua Wang
Medicine.2022; 101(42): e31215. CrossRef
Synovial sarcoma in children: A 15-YEAR experience at a tertiary pediatric center in Argentina
E. Rossetti, G. Gonzalez Diaz, J. Lopez Marti, S. Innocenti, W. Cacciavillano, G. Felizzia, M. Viso, M.L. Ramos, P. Zubizarreta, A. Rose
Pediatric Hematology Oncology Journal.2021; 6(4): 175. CrossRef
Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
Dennis Christoph Harrer, Sebastian Buschauer, Ulrich Sterz, Karin Menhart, Christina Wendl, Daniel Heudobler, Matthias Grube, Tobias Pukrop, Wolfgang Herr, Martin Vogelhuber
Frontiers in Oncology.2021;[Epub] CrossRef
Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice
Waleed A. Q. Hailan, Faisal M. Abou-Tarboush, Khalid M. Al-Anazi, Areeba Ahmad, Ahmed Qasem, Mohammad Abul Farah
Drug and Chemical Toxicology.2020; 43(2): 158. CrossRef
Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma
Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim
Translational Oncology.2019; 12(2): 269. CrossRef
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
Laboratory Investigation.2019; 99(9): 1309. CrossRef
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model
Kentaro Miyake, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Norihiko Sugisawa, Jun Ho Park, Sahar Razmjooei, Yuki Katsuya, Maryam Barangi, Yunfeng Li, Scott D. Nelson, Takashi Murakami, Yuki Homma, Yukihiko Hiroshima, Ryusei Matsuyama, Michael Bouve
Biomedicine & Pharmacotherapy.2019; 117: 109093. CrossRef
Adipogenesis induces growth inhibition of dedifferentiated liposarcoma
Yu Jin Kim, Dan Bi Yu, Mingi Kim, Yoon‐La Choi
Cancer Science.2019; 110(8): 2676. CrossRef
Leiomyosarcoma of the Stomach with Metastasis to the Liver: A Case Report With Review of the Literature
Varshil Mehta, Monali Rajawat, Sameer Rastogi, Ravi H Phulware, Roman Mezencev
Future Science OA.2018;[Epub] CrossRef
Systemic treatment in adult uterine sarcomas
I.M.E. Desar, P.B. Ottevanger, C. Benson, W.T.A. van der Graaf
Critical Reviews in Oncology/Hematology.2018; 122: 10. CrossRef
Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature
Tomoko Yoshimoto, Shinichiro Kobayashi, Kengo Kanetaka, Kazuma Kobayashi, Yasuhiro Nagata, Michi Morita, Yuriko Isagawa, Naoe Kinoshita, Mitsuhisa Takatsuki, Susumu Eguchi
Surgical Case Reports.2018;[Epub] CrossRef

13,926 View
371 Download
19 Web of Science
21 Crossref

Wernicke's Encephalopathy in Advanced Gastric Cancer: Eun Suk Jung, Obin Kwon, Soo Hyun Lee, Ki Byung Lee, Joo Hoon Kim, Sang Hyun Yoon, Gun Min Kim, Hei-Cheul Jeung, Sun Young Rha; Cancer Res Treat. 2010;42(2):77-81. Published online June 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.2.77

Abstract PDF PubReader ePub

Purpose

With their prolonged survival and malnutrition, cancer patients, and especially gastrointestinal (GI) tract cancer patients, can develop Wernicke's encephalopathy (WE). The aim of this study is to remind physicians of the importance of WE and prompt management in patients with GI tract cancer.

Materials and Methods

This study is a retrospective review of 2 cases of WE in advanced gastric cancer (AGC) patients, and we review the literature for cases of GI tract cancer related to WE.

Results

A 48-year-old female with AGC presented dizziness and diplopia for 5 days and a 20 kg weight loss. Neurologic exam showed nystagmus and gaze disturbance. Her symptoms improved after daily parenteral injection of thiamine 100 mg for 17 days. A 58-year-old female with AGC presented with sudden disorientation, confusion and 15 kg weight loss. Neurologic exam showed gaze limitation and mild ataxia. Despite daily parenteral injection of thiamine 100 mg for 4 days, she died 5 days after the onset of neurologic symptoms. Combining the cases noted in the literature review with our 2 cases, the 7 gastric cancer cases and 2 colorectal cancer cases related to WE showed similar clinical characteristics; 1) a history of long-period malnutrition and weight loss, 2) relatively typical neurologic signs and symptoms and 3) specific magnetic resonance image findings. Except for 2 patients who had irreversible neurologic symptoms, the other 7 patients were improved with prompt thiamine treatment.

Conclusion

It is important to consider WE in GI tract cancer patients with acute neurologic symptoms and who are in a state of malnutrition. Thiamine should be given as soon as possible when WE is suspected.

Citations

Citations to this article as recorded by

Duodenal Adenocarcinoma in the Setting of Bariatric Surgery: A Perfect Storm for Wernicke’s Encephalopathy
Aliza Gross, Allen T Yu, Jacques Lara-Reyna, Koji Park, Eugenius J Harvey
Cureus.2023;[Epub] CrossRef
Thiamine deficiency in pregnancy and lactation: implications and present perspectives
Ozaifa Kareem, Sobia Nisar, Masood Tanvir, Umar Muzaffer, G. N. Bader
Frontiers in Nutrition.2023;[Epub] CrossRef
Beware of lethal Wernicke's encephalopathy after cytoreductive surgery with HIPEC for peritoneal pseudomyxoma: Case report of morbidity and mortality review
Oumayma Lahnaoui, Nezha EL Bahaoui, Sara El Atiq, Laila Amrani, Mohammed Anass Majbar, Amine Benkabbou, Raouf Mohsine, Amine Souadka
International Journal of Surgery Case Reports.2022; 98: 107500. CrossRef
Thiamine deficiency unrelated to alcohol consumption in high‐income countries: a literature review
Filomena Gomes, Gilles Bergeron, Megan W. Bourassa, Philip R. Fischer
Annals of the New York Academy of Sciences.2021; 1498(1): 46. CrossRef
WERNICKE ENCEPHALOPATHY IN A PATIENT WITH GASTRIC CANCER RECURRENCE AFTER UPPER GASTROINTESTINAL SURGERY: A CASE REPORT AND REVIEW OF THE LITERATURE
Zining Liu, Xin Ye, Jiejin Yang, Zeyang Chen
Gastroenterology Nursing.2020; 43(6): 463. CrossRef
Wernicke's encephalopathy in a subject with enter-colic fistula
Daniele Canova, Paola Scalon, Fabio Monica, Stefano A. Grassi, Anna Giacomin, Tiziana Tumelero, Gaetano Mastropaolo, Francesco Malfa
Gazzetta Medica Italiana Archivio per le Scienze Mediche.2019;[Epub] CrossRef
Wernicke's encephalopathy in a patient with non-Hodgkin's lymphoma post-Autologous HSCT
João Paulo de Vasconcelos Leitão, Romélia Pinheiro Gonçalves Lemes, Maritza Cavalcante Barbosa, Beatriz Stela Gomes de Souza Pitombeira Araújo, Karine Sampaio Nunes Barroso, Jacques Kaufman, Talyta Ellen de Jesus dos Santos, Anna Thawanny Gadelha Moura, A
Revista da Associação Médica Brasileira.2018; 64(10): 882. CrossRef
Wernicke encephalopathy as initial presentation of lymphoma
Ju Hyun Seo, Ju Hee Kim, Der Sheng Sun, Hye Sung Won, Jeong Wook Park, Yoon Ho Ko
The Korean Journal of Internal Medicine.2017; 32(6): 1112. CrossRef
The Role of Thiamine and Effects of Deficiency in Dogs and Cats
Georgia Kritikos, Jacqueline Parr, Adronie Verbrugghe
Veterinary Sciences.2017; 4(4): 59. CrossRef
Association between malignancy and non-alcoholic Wernicke's encephalopathy: a case report and literature review
Evan Y. Choi, William A. Gomes, Missak Haigentz, Jerome J. Graber
Neuro-Oncology Practice.2016; 3(3): 196. CrossRef
Wernicke encephalopathy as rare complication of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Antonio Macrì, Francesco Fleres, Antonio Ieni, Maurizio Rossitto, Tommaso Mandolfino, Salvatore Micalizzi, Francesco Iaropoli, Carmelo Mazzeo, Massimo Trovato, Eugenio Cucinotta, Edoardo Saladino
International Journal of Surgery Case Reports.2015; 16: 29. CrossRef
Two Cases of Wernicke's Encephalopathy That Developed during Total Parenteral Nutrition in Colon Cancer Patients Treated with 5-Fluorouracil-based Chemotherapy
Kyung Pyo Cho, Jae Sung Lee, Ji Seok Seong, Yong Moon Woo, Young Jun Cho, Beom Jin Jeong, Jee Hoon Sohn, Su-Jung Kim
The Korean Journal of Gastroenterology.2014; 64(3): 158. CrossRef
Wernicke's encephalopathy in a patient with gastric carcinoma: a diagnosis not to miss
Chandrashekar Udyavara Kudru, Shivashankara Kaniyoor Nagiri, Sandeep Rao
BMJ Case Reports.2014; 2014: bcr2013203511. CrossRef
Wernicke-Korsakoff Syndrome in Primary Peritoneal Cancer
Ki Hyang Kim
Case Reports in Oncology.2013; 6(3): 593. CrossRef

12,419 View
86 Download
14 Crossref

Prognosis of pN3 Stage Gastric Cancer: Jung Ryun Ahn, Minkyu Jung, Chan Kim, Min Hee Hong, Hong Jae Chon, Hye Ryun Kim, Hei-Cheul Jeung, Woo Jin Hyung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha; Cancer Res Treat. 2009;41(2):73-79. Published online June 30, 2009; DOI: https://doi.org/10.4143/crt.2009.41.2.73

Abstract PDF PubReader ePub

Purpose

The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features.

Materials and Methods

Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer. They underwent both gastrectomy and lymphadenectomy with a curative aim. We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis.

Results

Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3. Among these 260 patients, 78 patients were classified as the pN3/M1 stage. For all the patients, the median follow-up period was 19 months (range: 1~108 months) and the median overall survival time was 16.2 months (95% CI, 14.1~18.3%). The 5-year survival rate of the pN3/M0 group was significantly higher than that of the pN3/M1 group (12.6% vs. 2.6%, respectively, p<0.0001). The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients.

Conclusion

The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group. An advanced T stage was a predictor for a poor prognosis for the pN3 patients. Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.

Citations

Citations to this article as recorded by

GSK461364A suppresses proliferation of gastric cancer cells and induces apoptosis
Dilara Ataseven, Şeyma Taştemur, Fatih Yulak, Sebahattin Karabulut, Mustafa Ergul
Toxicology in Vitro.2023; 90: 105610. CrossRef
HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3
Wei-Jie Zang, Yi-Lin Hu, Chen-Yu Qian, Ying Feng, Jia-Zhou Liu, Jun-Ling Yang, Hua Huang, Yi-Zhun Zhu, Wan-Jiang Xue
British Journal of Cancer.2022; 127(2): 237. CrossRef
Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer
Zhe Gong, Jieyun Zhang, Weijian Guo
Cancer Medicine.2020; 9(23): 9052. CrossRef
S100A10 Accelerates Aerobic Glycolysis and Malignant Growth by Activating mTOR-Signaling Pathway in Gastric Cancer
Yan Li, Xiao-Yu Li, Li-Xiang Li, Ru-Chen Zhou, Yinhe Sikong, Xiang Gu, Bi-Ying Jin, Bing Li, Yan-Qing Li, Xiu-Li Zuo
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Oncología personalizada: principales biomarcadores en el pronóstico y tratamiento de tumores sólidos
Marta Molina Romero, Emilio José Laserna Mendieta, Gema María Varo Sánchez, María Concepción Alonso-Cerezo, María Orera Clemente
Revista del Laboratorio Clínico.2019; 12(3): e1. CrossRef
Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?
J. Zhang, S. Zou, R. Luo, Z. Zhu, Z. Wang, H. Xu, B. Huang
Clinical and Translational Oncology.2019; 21(12): 1699. CrossRef
Reduced expression of Rap1GAP as a prognostic biomarker for primary gastric cancer patients
Jingjing Zhao, Cong Mai, Desheng Weng, Changlong Chen, Ziqi Zhou, Yuan Liu, Zhiwei Zhou, Peng Wang
Cancer Biomarkers.2018; 22(3): 375. CrossRef
Prognostic Discrepancy of the 6th and 7th UICC N Classification for Lymph Node Staging in Gastric Cancer Patients after Curative Resection
Sung Jin Oh, Byoung Jo Suh, Jong Kwon Park, Sung Don Oh, Hang Jong Yu
Case Reports in Oncology.2017; 10(1): 57. CrossRef
Gastric biomarkers: a global review
Nick Baniak, Jenna-Lynn Senger, Shahid Ahmed, S. C. Kanthan, Rani Kanthan
World Journal of Surgical Oncology.2016;[Epub] CrossRef
MiR 21‐5p as a predictor of recurrence in young gastric cancer patients
Soo‐Kyung Park, Young Soo Park, Ji Yong Ahn, Eun‐Ju Do, Dongho Kim, Jee Eun Kim, kyoungwon Jung, Jeong‐Sik Byeon, Byong Duk Ye, Dong Hoon Yang, Sang Hyoung Park, Sung Wook Hwang, Hwoon‐Yong Jung, Seung‐Jae Myung
Journal of Gastroenterology and Hepatology.2016; 31(8): 1429. CrossRef
Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer
Dongying Gu, Mulong Du, Cuiju Tang, Haiyan Chu, Zhi Xu, Xinyin Huo, Weida Gong, Yongfei Tang, Jianwei Zhou, Na Tong, Yong Xu, Zhengdong Zhang, Meilin Wang, Jinfei Chen
Environmental and Molecular Mutagenesis.2014; 55(5): 421. CrossRef
Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer
Bang Wool Eom, Jungnam Joo, Young-Woo Kim, Daniel Reim, Ji Yeon Park, Hong Man Yoon, Keun Won Ryu, Jong Yeul Lee, Myeong-Cherl Kook
Surgery.2014; 155(3): 408. CrossRef
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer
Yonghui Wu, Heike Grabsch, Tatiana Ivanova, Iain Beehuat Tan, Jacinta Murray, Chia Huey Ooi, Alexander Ian Wright, Nicholas P West, Gordon G A Hutchins, Jeanie Wu, Minghui Lee, Julian Lee, Jun Hao Koo, Khay Guan Yeoh, Nicole van Grieken, Bauke Ylstra, Sun
Gut.2013; 62(8): 1100. CrossRef
Validity and Necessity of Sub-classification of N3 in the 7thUICC TNM Stage of Gastric Cancer
Fang-Xuan Li, Ru-Peng Zhang, Han Liang, Ji-Chuan Quan, Hui Liu, Hui Zhang
Asian Pacific Journal of Cancer Prevention.2013; 14(3): 2091. CrossRef
Is the New Seventh AJCC/UICC Staging System Appropriate for Patients with Gastric Cancer?
Hong Man Yoon, Keun Won Ryu, Byung Ho Nam, Soo Jeong Cho, Sook Ryun Park, Jong Yeul Lee, Jun Ho Lee, Myeong-Cherl Kook, Il Ju Choi, Young-Woo Kim
Journal of the American College of Surgeons.2012; 214(1): 88. CrossRef
Comparison of the 6th and 7th Editions of the UICC TNM Staging System for Gastric Cancer: Results of a Chinese Single-Institution Study of 1,503 Patients
Wei Wang, Xiao-wei Sun, Chao-feng Li, Lin Lv, Yuan-fang Li, Ying-bo Chen, Da-zhi Xu, Rajiv Kesari, Chun-yu Huang, Wei Li, You-qing Zhan, Zhi-wei Zhou
Annals of Surgical Oncology.2011; 18(4): 1060. CrossRef

12,155 View
76 Download
16 Crossref

Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer: Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee; Cancer Res Treat. 2009;41(1):12-18. Published online March 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.1.12

Abstract PDF PubReader ePub

Purpose

Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.

Materials and Methods

One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m²) or cisplatin (60 mg/m²) was given over 1 hour with 5-FU (1 gm/m²) on days 1~5 every 4 weeks.

Results

At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.

Conclusion

Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.

Citations

Citations to this article as recorded by

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef
Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
Chemical Physics Letters.2024; 842: 141191. CrossRef
Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
S. Shruthi, K. Bhasker Shenoy
ChemistrySelect.2024;[Epub] CrossRef
Recent Advances on Pt-Based Compounds for Theranostic Applications
Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
Molecules.2024; 29(15): 3453. CrossRef
Hallmarks of anticancer and antimicrobial activities of corroles
Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
Drug Resistance Updates.2023; : 100931. CrossRef
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules.2022; 27(8): 2466. CrossRef
Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
Coordination Chemistry Reviews.2022; 472: 214790. CrossRef
Metalofármacos en la terapia contra el cáncer
Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
TECNOCIENCIA Chihuahua.2022; 16(3): e1010. CrossRef
Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Dan Gibson
Journal of Inorganic Biochemistry.2021; 217: 111353. CrossRef
Monofunctional Platinum(II) Anticancer Agents
Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
Pharmaceuticals.2021; 14(2): 133. CrossRef
Pt(IV) Prodrugs with NSAIDs as Axial Ligands
Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
International Journal of Molecular Sciences.2021; 22(8): 3817. CrossRef
Multi-action Pt(IV) anticancer agents; do we understand how they work?
Dan Gibson
Journal of Inorganic Biochemistry.2019; 191: 77. CrossRef
TOXview: a novel graphical presentation of cancer treatment toxicity profiles
Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Acta Oncologica.2019; 58(8): 1138. CrossRef
Photoactivated platinum-based anticancer drugs
Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
Coordination Chemistry Reviews.2018; 376: 405. CrossRef
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
Cancer Chemotherapy and Pharmacology.2018; 81(6): 981. CrossRef
An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
Management Science.2016; 62(5): 1511. CrossRef
Platinum(iv) anticancer prodrugs – hypotheses and facts
Dan Gibson
Dalton Transactions.2016; 45(33): 12983. CrossRef
Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
Journal of Inorganic Biochemistry.2016; 162: 109. CrossRef
VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
Molecular Pharmaceutics.2016; 13(11): 3712. CrossRef
Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
AIP Advances.2014;[Epub] CrossRef
Nanocarriers for delivery of platinum anticancer drugs
Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
Advanced Drug Delivery Reviews.2013; 65(13-14): 1667. CrossRef
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
Investigational New Drugs.2012; 30(3): 1224. CrossRef
Cellular interactions of platinum drugs
Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
Inorganica Chimica Acta.2012; 393: 75. CrossRef
What do we know about the reduction of Pt(IV) pro-drugs?
Ezequiel Wexselblatt, Dan Gibson
Journal of Inorganic Biochemistry.2012; 117: 220. CrossRef
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
European Journal of Surgical Oncology (EJSO).2011; 37(6): 466. CrossRef
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
Dalton Transactions.2010; 39(35): 8113. CrossRef

12,316 View
114 Download
26 Crossref

A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer: Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim; Cancer Res Treat. 2007;39(1):6-9. Published online March 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.1.6

Abstract PDF PubReader ePub

Purpose

To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy.

Materials and Methods

Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m² by 3-hour infusion on day 1, and cisplatin, 60 mg/m² by 1 hour infusion on day 1, with the treatment repeated every 3 weeks.

Results

37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%).

Conclusion

The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.

Citations

Citations to this article as recorded by

Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
Cancer Management and Research.2022; Volume 14: 2825. CrossRef
Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
Japanese Journal of Clinical Oncology.2009; 39(4): 237. CrossRef

9,438 View
45 Download
2 Crossref

Radical Radiotherapy for Locally Advanced Cancer of Uterine Cervix: Jeung Eun Lee, Seung Jae Huh, Won Park, Do Hoon Lim, Yong Chan Ahn, Chang Soo Park, Byoung Gie Kim, Duk Soo Bae, Je Ho Lee, Chong Taik Park, Tae Jin Kim, Kyung Taek Lim, Hwan Wook Chung, Ki Heon Lee, Jae Uk Shim; Cancer Res Treat. 2004;36(4):222-227. Published online August 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.4.222

Abstract PDF PubReader ePub

Purpose

This study was performed to evaluate the treatment results, prognostic factors and complication rates in patients with locally advanced cancer of uterine cervix after radiotherapy with high-dose rate (HDR) brachytherapy.

Materials and Methods

One hundred and twenty patients with a locally advanced (stages IIB~IVA according to FIGO classification) carcinoma of the uterine cervix were treated with radiotherapy at the Department of Radiation Oncology, Samsung Medical Center between September 1994 and December 2001. The median age of the patients was 61 years (range 29 to 81). Sixty-one, 56 and 3 patients had FIGO stage IIB, III, and IV diseases, respectively. All patients were given external beam radiotherapy over the whole pelvis (median 50.4 Gy) and HDR intracavitary brachytherapy, with a median of 4 Gy per fraction, to point A. Twenty-one patients received chemotherapy, of which 13 and 21 received neoadjuvant chemotherapy and concurrent chemotherapy, respectively, during the first and fourth weeks of external beam radiotherapy. The chemotherapy was not randomly assigned and the median follow-up time was 28.5 months (range: 6~100 months).

Results

The three- and 5-year overall survival (OS) and disease-free survival (DFS) rates were 64.4 and 57.0%, and 63.7 and 60.2%, respectively. The 5-year OS and DFS rates of the patients at stages IIB, III and IV were 60.2, 57.9 and 33.3%, and 57.4, 65.4 and 33.3%, respectively. Univariate analysis indicated that the FIGO stage, overall treatment time (OTT) and treatment response were significant variables for the OS (p=0.035, p=0.0649 and p=0.0009) and of the DFS (p=0.0009, p=0.0359 and p=0.0363). Multivariate analysis showed that the treatment response was the only significant variable for the OS (p=0.0018) and OTT for the DFS (p=0.0360). The overall incidence of late complications in the rectum and bladder were 11.7 and 6.7%, respectively. In addition, insufficiency fractures were observed in 7 patients (5.8%).

Conclusion

The results of this study suggest that radical radiotherapy with HDR brachytherapy was appropriate for the treatment of locally advanced uterine cervix cancer. Also, the response after treatment and OTT are significant prognostic factors.

Citations

Citations to this article as recorded by

Bilateral cervical cancer in a complete septate uterus with a double cervix and vagina: a case report
Li Wang, Zi Liu
Journal of International Medical Research.2023;[Epub] CrossRef
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)
Eleonor Rivin del Campo, Oscar Matzinger, Karin Haustermans, Didier Peiffert, Robert Glynne-Jones, Kathryn A. Winter, Andre A. Konski, Jaffer A. Ajani, Jean-François Bosset, Jean-Michel Hannoun-Levi, Marc Puyraveau, A. Bapsi Chakravarthy, Helen Meadows, J
European Journal of Cancer.2019; 121: 130. CrossRef
Predictors of Radiation Field Failure After Definitive Chemoradiation in Patients With Locally Advanced Cervical Cancer
Hyo Sook Bae, Yeon-Joo Kim, Myong Cheol Lim, Sang-Soo Seo, Sang-yoon Park, Sokbom Kang, Sun Ho Kim, Joo-Young Kim
International Journal of Gynecological Cancer.2016; 26(4): 737. CrossRef
High expression of mTOR is associated with radiation resistance in cervical cancer
Min-Kyu Kim, Tae-Joong Kim, Chang Ok Sung, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae
Journal of Gynecologic Oncology.2010; 21(3): 181. CrossRef
Increased expression of pAKT is associated with radiation resistance in cervical cancer
T-J Kim, J-W Lee, S Y Song, J-J Choi, C H Choi, B-G Kim, J-H Lee, D-S Bae
British Journal of Cancer.2006; 94(11): 1678. CrossRef

8,905 View
53 Download
5 Crossref

5-Fluorouracil, Leucovorin ( FL ) Combination Chemotherapy in Advanced or Recurrent Colo - rectal Cancer: Jeong Hwan Cho, Hyuk Chan Kwon, Hyo Jin Kim; J Korean Cancer Assoc. 1999;31(5):1003-1010.

Abstract PDF: PURPOSE
We studied the effectiveness and toxicities of 5-fluorouracil+leucovorin, combination chemotherapy in advanced or recurred colo-rectal cancer patients, who didn't have previous chemotherapy and enrolled from August 1993 to July 1998.
MATERIALS AND METHODS
All patients were treated with leucovorin followed by 5-fluorouracil for 5 consecutive days every 4 weeks. Among 43 patients who were enrolled, 40 patients received treatment at least 2 courses, and they were evaluable. Male to female ratio was 21 to 19. In serum CEA level, 27 patients were greater than 5 ng/ml and 13 were less than 5 ng/ml. And primary site was colon in 21 patients and rectum in 19 patients.
RESULTS
The complete response rate was 7,5% and the partial response rate was 25%. The median survival duration was 14.7 months, the median response duration was 16.0 months, and median time to progression was 7.3 months. In the analysis of response, survival duration, time to progression according to various characteristics of patients, serum CEA level and liver involvement were revealed significant difference in survival duration, time to progression (p=0.0122, 00350 & 0.0202, 0.0123) on univariate analysis, but no significant difference on multivariates. Hematologic and non-hematologic toxicities were mild and tolerable.
CONCLUSION
This study indicates that the combination of 5-fluorouracil (370 mg/m) and leucovorin (20 mg/m) is effective and tolerable regimen in advanced or recurred colo-rectal cancer patients without previous chemotherapy.

4,667 View
46 Download

Correlation between VEGF Expression and Angiogenesis in Advanced Gastric Carcinoma: Young Bae Kim, Jee Young Han, Sang Hyun Lee, Hae Seung Han, Tae Sook Kim, Young Chae Chu, Tae Sook Hwang; J Korean Cancer Assoc. 1998;30(6):1061-1068.

Abstract PDF: PURPOSE
VEGF is thought to be an important angiogenic factor playing significant a role in the aggressiveness of malignant tumor by stimulating neovascularization. We morphologically investicated the tumor angiogenesis in terms of the presence of VEGF expression in advanced gastric carcinoma.
MATERIALS AND METHODS
We performed immunohistochemical stains for VEGF, CD 34, and MIB-1 (Ki-67) on the 51 paraffin-embedded tissue sections. The degree of angiogenesis was determined by counting microvessel densities and their Ki-67 labelling indices of endothelial cells within the tumors. We evaluated the correlation between the expression of VEGF, angiogenesis and clinicopathologic factors such as histologic differentiation, depth of invasion, and lymph node metastasis.
RESULTS
Immunoreactivity for VEGF revealed positivity in 34 out of 51 cases (66.7%). Microvessel densities and Ki-67 labelling indices of endothelial cells reflecting angiogenesis were higher in VEGF-positive tumors than VEGF-negative tumors. There were no conelations between VEGF expression, histologic differentiation and the depth of invasion. We failed to evaluate the conelation of VEGF expression and lymph node metastasis.
CONCLUSION
This study suggests that VEGF expressian is closely related to tumor asso- ciated angiogenesis in advanced gastric carcinoma. Considering that tumor growth depends on angiogenesis, therapies reducing VEGF may be a means of inhibiting angiogenesis and tumor aggressiveness.

3,357 View
14 Download

Cispatin , Etoposide , Leucovorin and 5-Fluorouracil ( PELF ) Combination Chemotherapy for Advanced Gastric cancer: Interim Report: Il Rang Park, Si Young Kim, Jeong Hee Kim, Hwi Joong Yoon, Kyung Sam Cho; J Korean Cancer Assoc. 1998;30(5):907-913.

Abstract PDF: PURPOSE
In attempt to provide a feasible chemotherapeutic regimen for advanced gastric cancer patients, the combination of cisplatin, epirubicin, leucovorin and fluorouracil (PELF) has been developed. A trial was performed to confirm the clinical activity, in terms of response rate and toxicity and duration of survival, of the PELF combination chemotherapy.
MATERIALS AND METHODS
From April 1995 to July 1997, patients with measurable unresectable and/or metastatic gastric cancer received PELF combination chemotherapy. The regimen consisted of cisplatin 40 mg/m2 IV on days 1 and 5; epirubicin 30 mg/m2 IV on days 1 and 5; 5-fluorouracil 300 mg/m2 and leucovorin 20 mg/m2 IV on days 1 through 4. The cycle was repeated every 3 weeks.
RESULT
Among 21 evaluable patients, 1 patient achieved complete response (5.3%) and 8 patients, partial response (42.1%). The median survival of overall patients was 36 weeks, the median time to progression of 21 evaluable patients was 27 weeks. There was severe myelosuppression; leucopenia 73.1%, WHO grade 3~4 11.5% of cycles. Non-hematologic toxicities were also severe nausea or vomiting in 100% of patients, grade 3~4 13.0% of patients, alopecia in 91.3% of patients, grade 3~4 52.2% of patients.
CONCLUSION
This study showed that the PELF combination is effective in overall response rates. However, it is not recommended for routine clinical use because of its toxicities. Further phase III study will be warranted.

3,270 View
17 Download

Selection of Surgical Procedure in the Elderly with Advanced Gastric Cancer: Hyeoung Joon Kim, Tae Kyung Sohn, Woo Joong Kim, Kyung Suk Chung; J Korean Cancer Assoc. 1998;30(5):892-899.

Abstract PDF: PURPOSE
The quality of life has become increasingly important as an outcome when assessing patients who have had surgery for advanced gastric cancer in the elderly. The purpose of this study was to study the validity of quality of postoperative life as a criterion in the decision-making process as well as the results of operation for advanced gastric cancer in the elderly.
MATERIALS AND METHODS
Spitzer's quality of life index, postoperative mortality and survival were evaluated in 67 patients(over 65 years of age) with advanced gastric cancer who had undergone operation between 1988 and 1997 at the Department of Surgery, Kangnam Sacred Heart Hospital.
RESULTS
The quality of life score and median survival correlated with TNM clinical stage(IIIa; 7.1+/-1.8, 36.0 months vs. IIIb: 5.8+/-2.8, 28.6 months vs. IV: 2.9+/-1.9, 4.5 months), resectability(reseetion: 5.9+/-2.7, 21.0 months vs. no resection: 3.0+/-2.0, 4.0 months), curability(curative operation: 6.5+/-2.4, 29.0 months vs. palliative operation: 3.3+/-2.4, 6.0 months), type of gastrectomy(subtotal gastrectomy: 6.4+/-2.7, 28.0 months vs. totai gastrectomy: 4.5+/-2.6, 9.0 months), but not with age or sex. There was a difference in operative mortality according to age group(65~70 years: 7.8% vs. >70 years: 18.8%), resectability(resection: 7.4% vs. no resection: 23.0%) and curability (curative operation: 2.3% vs. palliative operation: 25.0%).
CONCLUSION
The results suggest that surgical resection offers the only chance for improved survival and qulaity of life. Gastric resection, even with total gastrectomy, can be undertaken to reduce tumor burden, decrease threats of obstruction, hemarrhage, or perforation and improve quality of life in the elderly if there is little coexisting impairment.

2,339 View
13 Download

The Effects of the Induction Chemotherapy on the Radical Radiotherapy in the Locally Advanced Cervical Cancer: Ki Mun Kang, Sei Chul Yoon, Hong Seok Jang, Mi Ryeong Ryu, Yeon Shil Kim, Sung Eun Namkoong, Seung Jo Kim; J Korean Cancer Assoc. 1998;30(4):762-771.

Abstract PDF: PURPOSE
We evaluated the prognostic factors, survivals and patterns of failure of the patients with locally advanced cervical cancer who received radical radiotherapy alone and induction chemotherapy followed by radiotherapy respectively.
MATERIALS AND METHODS
Between May 1985 to December 1992, one hundred and sixty three patients with locally advaneed cervical cancer received curative radiotherapy. Patients were divided into two groups: control group included 69 patients who received curative radiotherapy and combined group included 94 patients who received induction chemotherapy followed by curative radiotherapy. The curative radiotherapy consisted of external pelvic radiotherapy and intracavitary brachytherapy. Induction chemotherapy was delivered in VBP (vincristine, bleomycin, cisplatin) and FP (5-FU, cisplatin). Follow up period ranged from 2 months to 99 months with median of 50 months.
RESULTS
The overall response rate was 94.2% in the control group and 89.4% in the combined group. The response rate by control group was 66.7% for CR (complete response), 27.5% for PR (partial response), 5.8% for NR (no response). The response rate by combined group of CR, PR, NR were 64.9%, 24.5%, 10.6%, respectively. There was no difference in response for control group and combined group (p> 0.05). The 5-year overall survival had no significant difference in between control group and combined group (54.6% vs. 57.3%). The 5-year disease free survival also had no significant difference (52.9% vs. 55.0%). In the control group, 23 patients (33.3%) had treatment failure: twelve (17.4%) at a local recurrence, 9 (13.0%) as distant metastasis, and 2 (2.9%) with both local recurrence and distant metastasis. In the combined group, Thirty patients (31.9%) failed therapy, with local recurrence in 21 patients (22.3%), distant metastasis in 7 patients (7.5%), and both in 2 patients (2.1%). The difference between the two groups was not significant in view of patterns of failure. The major toxicities were nausea/ vomiting, leukopenia, anemia, and diarrhea. The prognostic factors affecting were hemoglobin level, KPS (karnofsky performance status), and treatment response in both group by multivariate analysis.
CONCLUSION
This study did not prove the efficacy of induction chemotherapy followed by radiotherapy in locally advanced cervical cancer.

3,130 View
21 Download

Results of Hyperthermic Treatment Combiced with Radiotherapy/Chemotherapy in Locally Advanced Inoperable Gastric Cancer: Chang Woo Moon, Ha Yong Yeom, Tae Sik Jung, Young Ho Kim, Ja Young Koo; J Korean Cancer Assoc. 1998;30(4):639-651.

Abstract PDF: PURPOSE
This retrospective study is conducted to evaluate the local response rate, survival rate, median survival times and complication of hyperthermic treatment combined with radiotherapy/chemotherapy in locally advanced inoperable gastric cancer.
MATERIALS AND METHODS
One hundred and twenty-seven patients treated with hyperthermia from April, 1992 to December, 1994 were enrolled. Among 127 patients, 13(10.2%) were treated with thermo-radiotherapy(Group I), 4(3.1%) were treated with thermo-radio-chemotherapy(Group II) and 110(86.6%) were treated with thermo-chemotherapy (Group III). Hyperfractionated radiotherapy(135 cGy/fr., 2 times/day) using 6-MV X-ray Linac was delivered with total doses of 40.5~67.5 Gy(median: 45 Gy). Chemotherapy by FI(5-FU+ Interferon) or EAP(Etoposide+ Adriamycin+ Cisplatin) regimens was administered. Hyperthermia using 8-MHz RF(radiofrequency) capacitive heating eqiupment (CANCERMIA GHT-8) was applied with interval of 2 times/week, 40~60 minutes /session within 10~15 minutes following radiation, and was simultaneously done with chemotherapy. The estimation of local response was used computed tomography and endoscopy, and was divided into complete response(CR), partial response(PR), and no response(NR). The survival rate was calculated by Kaplan-Meier method.
RESULTS
Overall local response rate(CR+ PR) was 68.5% with 6.3% in CR and 62.2% in PR. The local response rates by treatment modality were 92.3% (CR: 15.4%, PR: 76.9%) in Group I, 100%(CR: 75.0%, PR: 25.0%) in Group II and 64.5%(CR: 2.7%, PR: 61.8%) in Group III. There was statistically significant difference(p=0.0001). The overall 1 and 2 years survival rates with median survival time(MST) were 20.5%, 7.1% with 9 months, respectively. The overall 1 and 2 years survival rates(with MST) by treatment modality were 7.7%, 0%(7 months) in Group I, 50.0%, 0%(9 months) in Group II and 20.9%, 8.2%(6 months) in Group III. There was no statistically significant difference. The incidence of side effect by heating was 3.1%(4 patients) and the most serious side effect was subcutaneous fat necrosis in anterior abdominal wall.
CONCLUSION
From this study we concluded that hyperthermic treatment combined with radiotherapy/chemotherapy may increase the local response rate in locally advanced inoperable gastric cancer.

2,537 View
20 Download

Case Report

A Case of Placental Metastasis from Advanced Gastric Carcinoma: Mi Sook Lee, Sang Hee Kim, Je Hwan Lee, Sung Bae Kim, Cheol Won Suh, Kyoo Hyung Lee, Jung Shin Lee, Woo Kun Kim, Sang We Kim; J Korean Cancer Assoc. 1998;30(3):608-612.

Abstract PDF: Placental and fetal involvement by matenal malignancy is rare. We report a case of placental metastasis from advanced gastric carcinoma in a 27 year-old woman. The patient also had disseminated bone metastasis, bone marrow involvement, malignant ascites, multiple lymphadenopathy, and disseminated intravascular coagulopathy. Cut surface of the placental body showed many, variable-sized, grayish white nodules and plaques. Light microscopic finding showed sheets of poorly differentiated adenocarcinoma in intervillous spaces. Villi were not invaded. Despite palliative chemotherapy the patient died of massive gastric cancer bleeding. But the patients child is alive and doing well with age of 11 months. We suggest that the presence of malignancy in pregnancy demands complete evaluation of the placenta and adequate follow-up of the infant for the sign of involvement.

2,531 View
18 Download

Original Articles

Combined Chemoradiation of Advanced Pancreatic Cancer: Jee Young Jang, Ki Mun Kang, In Ah Kim, Ihi Bong Choi, Jai Hak Lee, Eung Kook Kim, Seung Nam Kim, Hee Sik Sun, Kyu Won Chung, Meung Kyu Choi, Joon Yeol Han, Han Lim Mun; J Korean Cancer Assoc. 1998;30(2):300-305.

Abstract PDF: PURPOSE
This study was designed to evaluate the survival rate and prognostic factor of patients with advanced pancreatic cancer who received chemoirradiation. MATERIAL AND METHODS: From March 1993 to November 1995, twenty patients with unresectable pancreatic cancer were treated at the Department of Therapeutic Radiology, St Mary's Hospital, Catholic University Medical College. There were 11 men and 9 women. Age at diagnosis ranged from 34 to 75 years. All patient were treated according to a protocol consisting of 40 Gy external radiation by split course concomitant with intravenous 5-fluorouracil (5-FU) 500 mg/m2 given in a bolus injection 4 hours before radiatian on each of the first 3 days of each treatment course. Among them, 5 patients received incomplete radiotherapy. The follow-up period ranged from 1.3 to 29 months.
RESULTS
In all the patients, median survival is 5.0 months and one and two-year overall survival rate was 34.3% and 25.8%, respectively. Median survival was 9.0 months and one-year survival rate was 33.3% in 15 patients with complete radiotherapy. The significant prognostic factors were stage, tumor location, and completion of chemoradio- therapy(p < 0.05).
CONCLUSION
A combination of radiotherapy and chemotherapy resulted in improved median survival. However, the significant prognostic factars affecting survival rate in this analysis need to be verified further through randomized trial.

2,339 View
13 Download

Phase 2 Trial of FLP ( 5-FU , Leucovorin , Cisplatin ) Combination Chemotherapy for Advanced Gastric Cancer: Young Iee Park, Moon Hee Lee, Sung Woo Han, Woo Jung Park, Dong Gyu Kim, Jin Lee, Jin Seok Ahn, Jung Ae Rhee, In Sook Woo, Young Suk Park; J Korean Cancer Assoc. 1998;30(1):55-62.

Abstract PDF: PURPOSE
Advanced gastric cancer, the most common malignancy in Korea is a kind of systemic disease. At dignosis, 50~80% of patients have systemic cancer. Therefore, the most patients require systemic chemotherapy. Cisplatin and 5-FU have been suggested to be active in the treatment of gastric cancer, a high response rate was observered with a combination of 5-FU infusion and cisplatin, and the biochemical modulation of 5-FU by leucovorin has been demonstrated to enhance the activity of 5-FU in gastrointestinal tract cancer.
MATERIALS AND METHODS
The patients with advanced gastric cancer whose disease had relapsed or unresectable were treated with 5-FU(800 mg/m2 12 hr IV infusion, D 1~5), leucovorin(20 mg/m2 IV, D 1~5, max. 30 mg), cisplatin(100 mg/m2 15min IV dripping, D1). The cycles of treatment were repeated at 3-weeks intervals.
RESULTS
Between Sep. 1994 and Aug. 1996, previously untreated 44 patients(39 eligible patients) were admitted to this study, the median age was 55 years(range 17~73) and male to female ratio was 20:19. The rate of complete remission was 5%(2/39), the rate of partial remission was 21%(8/39). The median-response duration was 26 weeks(5+~38+ ). The median-time to progression was 25 weeks(4+~62+). The range of overall survival time was from 4 to 62+ weeks. 24 weeks survival rate was 71.5% but the median survival time was not reached. The leukopenia and anemia were the main hematologic toxicities. Non-hematologic side effects were nausea, vomiting, diarrhea, stomatitis, peripheral neuropathy. These toxicities were observed commnonly, but tolerable. Two treatment-related deaths were associated with sepsis.
CONCLUSION
Based on these results, FLP combination chemotherapy seems to be a moderate efficacy for advanced gastric cancer with tolerable toxicities. To confirm the efficacy further, the long-term follow up and a large scale of clinical studies are needed.

3,013 View
14 Download

A Phase II Study of AP (Doxorubicin, Cisplatin) Chemotherapy in Patients with Advanced Hepatocellular Carcinoma: Jung Ae Lee, Yoon Koo Kang, Chang Min Kim, Jin Oh Lee, Tae Woong Kang; J Korean Cancer Assoc. 1997;29(1):103-110.

Abstract PDF: PURPOSE
Hepatocellular carcinoma (HCC) is the most common form of primary hepatic carcinoma and is considered to be a highly malignant tumor with poor prognosis. We evaluated the efficacy and toxicities of AP (doxorubicin, cisplatin) comnination chemotherapy in hepatocellular carcinoma.
MATERIALS AND METHODS
Between October 1989 and February 1991, 21 previously untreated patients with advanced hepatocellular carcinoma were entered and treated with AP combination chemotherapy (adriamycin 60 mg/m2, D1 and cisplatin 60 mg/m2, D1, repeated every 3 weeks).
RESULTS
Among 14 evaluable patients, there was no complete response and 5 patients (36%; 95% C.I=10~62%) achieved partial response. The median survival time of all 21 patients was 17 weeks, and 63 weeks in responders (n=5) and 14 weeks in nonresponders (n=16), and the difference in two groups was statistically significant (p<0.05). The median time to progression of 14 evaluable patients was 13 weeks, and 49 weeks in the responders (n=5) and 6 weeks in the nonresponders (n=9), and the difference in two groups was statistically significant (p<0.05). Myelosuppression was minimal and non-hematologic toxicities were gererally mild and well tolerated.
CONCLUSION
The results suggest that the combination chemotherpy of AP seems to be an effective regimen for hepatocellular carcinoma. Further trials are recommended for its true efficacy.

4,719 View
56 Download

Clinical Trial of Human Recombinant Interleukin-2 ( IL-2: Joung Soon Jang, Jae Bum Jun, Joon Soo Hahm, Min Ho Lee, Il Young Choi, Te June Chung; J Korean Cancer Assoc. 1990;22(1):96-106.

Abstract PDF: The effects of immunotherapy with IL-2 were evaluated in 10 patients with advanced cancers for whom standard anticancer chemotherapy had been ineffective from Apr. 1988 to Mar. 1989. Of total 10 patients, five were treated witn 24 hr continuous IV infusion of IL-2 with the dosage of 1 x 10(4) u/kg/day or 1 x 10(5) u/kg/day respectively for 5 days and another five with intraperitoneal bolus infusion of IL-2 with the dosage of 1 x10(4) u/kg/day or 1 x 10(5) u/kg/day after removal of ascites by paracenthesis for 5 days. Of the 10 evaluable patients, 9 (90%) patients had no response and only 1 (10%) had minimal response. One patient who had minmal response had squamous cell ca of esophagus and has received IL-2 intravenously. Most common side effects were fever and chills and they could be prevented or alleviated by use of NSAIDs or IV infusion of Meperidine in severe cases. Serious side effects were capillay leak syndrome and its complication which show hypotension, generalized edema, weight gaine and azotemia. GI symptom, rigor and skin lesion were also obseved. But pulmonary edema was not observed. All of the above side effects were well overcome by conservative management. In the intraperitoneal infusion group the side effects occurred less frequently than IV infusion group. Anemia, neutropenia, eosinophilia, azotemia and abnormal liver function test were observed, but they have returned to normal range after discontinuation of IL-2 infusion. The absolute lymphocyte counts decreased I day after IV infusion of IL-2 and came back to show revound lymphocytosis from the next day after discontinuation of IL-2 infusion. They returned to pretreatment level from the 4th day of discontinuation of IL-2 infusion. In the intraperitoneal infusion group total WBC counts in ascites began to increase from 24 hrs after IL-2 infusion and reached peak at the end day of infusion. They began to decreased with discontinuation of infusion. Compared with WBC counts in ascites, those in peripheral blood showed delayed increase. In conclusion, 1 x 10' and 1 x 10 u/kg/day infusion of IL-2 were enough to increase the lymphocyte pool in vivo respectively, although no effective clinical response was obtained. There was no difference in the clinical and side effects between 1 x 10(4) and 1 x 10(5) u/kg/day infusion groups. This study warrants for further investigation into the determination of effeective therapeutic concentration of IL-2 and its route of adminstration.

2,769 View
15 Download

A Phase 2 Study on Combined 5 - Fluorouracil , Etoposide , Doxorubicin and Cisplatin ( F - EAP ) in Patients with Advanced Gastric Cancer: J Korean Cancer Assoc. 1994;26(1):9-16.

Abstract PDF: 5-Fluorouracil(5-FU), as a single agent, has a modest but reproducible activity against gastric cancer and continuous infusion of 5-FU is associated with less myelosuppresion. It has been reported that combination of etoposide, doxorubicin, and cisplatin(EAP) was very active in advanced gastric carcinoma with an overall response rate of 64% including 21% complete response from the German investigators. A phase II study of the combination of 5-FU infusion, etoposide, doxorubicin and cisplatin(F-EAP), which regimen has been demonstrated to have the different mechanisms of action and synergism between each of drugs in vitro and in vivo, was performed in attempts to evaluate the antitumor activity in patients with advanced gastric cancer. Fifty-five previously untreated patients with surgically unreasectable or metastatic advanced gastric adenocarcinoma were treated with 5-FU(800 mg/m, days 2, 3, and 4), etoposide(70 mg/m, days 2, 3, and 4), doxorubicin(30 mg/m, day 1), and cisplatin(60 mg/m(2), day 1) repeated every 26 days. Objective responses were observed in 14 of 47(30%) evaluable patients, and the median duration of response was 21 weeks(l3~60+ ). The median survival time of 47 evaluable patients was 40 weeks(16~62). F-EAP therapy was associated with mild myelosuppression. The common non-hematologic toxieities were nausea/vomiting(94%), mucositis(32%), peripheral neuropathy (15%), and infection(11%), but the majority of these toxicities were mild to moderate and well tolerated. These results suggest that F-EAP regimen has a modest antitumor activity in terms of response rate and duration of response, and is relatively well tolerated in advanced gastric cancer.

2,565 View
15 Download

Second - line , Chemotherapy with 5 - Fluorouracil Etoposide , Doxorubicin , Cisplatin , Cyclophosphamide , Adriamycin , Vincristine , Predais: Heung Moon Chang, Hyun Ah Kim, Won Seok Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1994;26(1):82-89.

Abstract PDF: There is no effective second-line chemotherapy for the advanced breast cancer. Previously CALGB reported that CAFVP combination chematherapy was more effective than the CMF or CMFVP combination chemotherapy for the advanced breast cancer. So we treated 38 advanced breast cancer patients with CAFVP combination chemotherapy, who had received previous chemotherapy, between June 1979 and September 1992. Median age was 41. 23 patients had prior mastectamy with adjuvant chemotherapy, 9 patients had prior mastectomy without adjuvant chemotherapy and 6 patients had initially stage IV lesions. All had been received prior chemotherapy. The menopausal status was as follows; 29 patients were premenopausal, 9 postmenopausaL The perfomance status was grade 0 to 1(ECOG) in 2l patients, 2 in 17. Treatment was cyclophosphamide 100 mg/m(2) po, day 1 l4, adriamycin 25 mg/m(2) iv, day 1 and 8, 5-fluorouracil 400 mg/m(2) iv, day 1 and 8, vincristine 1.4 mg/m iv, day 1 and 8, and pred- nisolone 60 mg/day po, day 1-14. The treatment was recycled every 4 weeks until the progression of the disease. Amang 26 patients with measurable lesions, 8(31%) achieved responses(l CR and 7 PR). Median duration of response was 7 months. Median survival for all patients was 20 months. Toxicity was as follows: leukopenia 35/, anemia 37%, thrombocytopenia 1%, N/V 21%. No treatment related death was observed during the treatment. It was concluded that CAFVP combination chemotherapy is not superior to other combination chemotherapy regimens, and myelosuppression is a major dose-limiting toxicity.

2,630 View
13 Download

Induction Chemotherapy and Surgery in Locally Advanced Stomach Cancer Showing Pancreas Involvement: Kyung Hee Lee, Jin Hyuk Choi, Sun Young Rha, Hye Ran Lee, Nae Chun Yoo, Ho Yeong Lim, Hyun Cheol Chung, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim; J Korean Cancer Assoc. 1994;26(3):377-385.

Abstract PDF: Gastric cancer is the most common malignancy in Korea. Cure for patients with gastric carcinoma can be achieved only by radical surgery. From August 1988 to May 1992, 25 patients with locally advanced unresectable gastric cancer received 5-FU(Fiuorouracil) + adriamydn + mitomycin-c or 5-FU + cisplatin based induction chemotherapy before surgem. The partial response rate after me- dian 3 cycles of induction cemotherapy was 52%, stable disease 12%, progressive disease 36%. Gastric resection was performed in 18 patients(72%); 13 patients(52%) underwent radical surgery and 5 patients(20%) underwent palliative surgery. Median survival of the patients who underwent cura- tive and palliative surgery was 24. 2 and 27 months, respectively. However, median survival of the patient who didnt undergo any surgery was only 6.5 months. The difference of median survival between curative surgery and none surgery group were significant statistically(P<0.03). Side effects of induction chemotherapy were acceptable and there were no life threatening toxicities In this study, half of the patients can undergo curative surgery after induction chemotherapy. We observe the long term survival in some patients after induction chemotherapy and surgery in loco-regionally advanced gsstric cancer. This therapeutic approch for the locally advanced stomach cancer seems to be feasible. But, prospective tandomized clinical trial is warranted in the future.

2,815 View
14 Download

First
Prev
Page of 2
Next
Last

Search